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1Introduction and outline of the thesis

INTRODUCTION AND OUTLINE OF THE THESIS
Cervical cancer screening in the Netherlands
Cancer screening
Cancer screening should be performed only in an organized setting with quality 
assurance at all levels of the screening programme and continuous monitoring. 
Benefits of cancer screening will be achieved only when compliance is high. 
Opportunistic screening activities causes unnecessary negative side-effects and 
should therefore be avoided. The effectiveness of cancer screening in the reduction 
of incidence and mortality depends on the sensitivity of the screening test, 
participation rate of the invited population, frequency of screening, number of 
screening tests offered during a lifetime, compliance with follow-up and effectiveness 
of early treatment.1
The history of the cervical cancer screening programme
In the early seventies, first cervical cancer screening with Papanicolaou (Pap) testing 
was started in the Netherlands with pilot projects in Utrecht, Nijmegen and Rotterdam. 
In the course of that decade, screening programmes were slowly spread to many 
districts around the country. In 1988 national implementation of the screening 
programme was conducted by nine regional screening centres in cooperation with 
general practitioners. W om en between the age of 35 and 53 were invited every 3 
years for cervical screening by means of a Pap smear. In total, wom en were invited 7 
times during their lives. The evidence gathered in the early 1990s, pointed towards a 
suboptimally performing programme, in terms of both the organization and the 
efficacy of screening of the target population.23 It was recognized that the participation 
rate was very low (40%-50%), the follow-up compliance was unsatisfactory, and 
follow-up policy varied due to a lack of clear-cut, nationally defined guidelines.
As the existing programme was considered ineffective, a reorganization took place in 
1996. The aim of the reorganization was to broaden the cohort of wom en eligible for 
screening w ithout increasing costs, to reduce the proportion of opportunistic 
screening, to redefine the Pap 2 classification (ASCUS smear) in order to reduce 
diagnostic differences between cytology laboratories, and to change the criteria for 
referral. The age range was changed into 30 till 60 years, and the screening interval 
was extended from 3 to 5 years, in order to leave the number of 7 invitations a lifetime 
unchanged.4 Cytological smears with cytom orphologic signs of inflammation and/or 
presence of specific microorganisms were no longer classified as Pap 2, but classified 
as within normal limits. Following the implementation of the new guidelines, the 
percentage of Pap 2 smears was reduced from 10% to 2%.5' 6 Additionally, normal 
smears w ithout endocervical cells were no longer repeated till a smear with 
endocervical cells was obtained, as there was doubt about the importance of these 
cells in cervical smears.7 “ Instead, these smears were repeated once after six months,
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and in case of a second smear w ithout endocervical cells, wom en were referred back 
to the 5-year scheme of the screening programme.
In 2002, repeat testing of normal smears w ithout endocervical cells was no longer 
advised. The lack of endocervical cells in an adequately taken smear encompassed no 
increased riskfor the presence, or a later presentation of cervical (pre-) malignancies.9' 
10 However, proper visual inspection of the cervix became, herewith, essential. 
A normal smear w ithout endocervical cells, and w ithout a clear visual inspection of 
the cervix or an abnormal cervix, is currently considered inadequate for diagnosis, 
with an advice to repeat the smear after 6 weeks.
To further increase the efficacy of the screening programme, negative triage with 
high-risk human papillomavirus (hrHPV) testing on repeat smears after a borderline 
smear, was incorporated into the national cervical cancer screening programme in 
2006 1'H6, as shown in figure 1. It is mandatory, that a clinically validated test with high 
inter-laboratory reproducibility is used for hrHPV testing.1726 Additionally, new 
laboratory techniques emerged and it was shown that liquid based cytology was at 
least as good as conventional cytology.27 28 Since 2008 both techniques have been 
approved for the national screening programme. The current programme is centrally 
coordinated by the National Institute for Public Health and the Environment (RIVM), 
which, on behalf of the Dutch Ministry of Health, bears the responsibility for quality 
control and financing. The organisation is largely decentralised, though currently, the 
number of decentral units is reduced from nine to five regional screening 
organisations.
The organization of the screening programme
The regional screening organization is responsible for the selection and invitation of 
wom en eligible for cervical cancer screening (30-60 yrs), and makes use of the 
Municipal Administration (GBA). W omen between the ages of 30 and 60 receive an 
invitation from the regional screening organization or from their general practitioner, 
once everyfive years.Together with the invitation, an information leaflet is sent, which 
enables wom en to make an informed choice whether to participate or not. W om en 
who decide not to take part, are requested to fill out an enclosed reply card in order 
to sign out either temporarily or definitively. The cervical smear is performed by 
general practitioners or their practice assistants. The smear is sent to the laboratory 
where it is assessed. The results are sent to the general practitioner who is responsible 
for communicating this result to the women, and responsible for appropriate referral 
of wom en to the gynaecologist when needed. The programme smears are free of 
charge. The non-attendees receive a reminder. W om en with normal smears will be 
invited for their next smear after five years. Smears with high-grade squamous 
intraepithelial lesions (HSIL) must be examined by the gynaecologist by colposcopy, 
during which biopsies are often taken to confirm the diagnosis. The follow-up scheme
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for borderline smears (atypical squamous cells of undetermined significance (ASC-US) 
or low-grade squamous intraepithelial lesions (LSIL)) is shown in Figure 1. Repeat 
smears after borderline results, and follow-up and treatment procedures at the 
gynaecology departm ent are not covered by the screening program and not free of 
charge, but normally paid for by health insurance.
Facts and figures
In the Netherlands, the target population consists of 3.6 million women, of which 
one-fifth is eligible annually. The participation rate of the national cervical cancer 
screening programme is about 65%.29 At the end of 1996, together with opportunistic 
screening, the percentage of wom en 30-60 years old with at least one smear in the 
previous five years was -70-80% and coverage of wom en with a Pap-smear at least 
once in their lifetime was 90%.20 The participation rate of the population based 
screening programme at the first screening round at the age of 30 is with -50% quite 
low.21 After the first screening round, the participation increases, however, in each 
following round from the age of 40 the participation declines, being 10-15% lower for 
the age group 50-59 than the age group 30-49.21-22 Opportunistic smears consist of 
smears taken outside the target age range or those taken after a too short interval. 
The opportunistic use of pap smears in the Netherlands is very low: 24 per 1000 
wom en in a 5-year period, being <2% of the total screening activity in 2003.29 24 The 
total annual number of smears is about 1.000.000, of which 450.000 are smears taken 
in the organized programme, 300.000 other primary smears and 250.000 secondary 
(follow-up) smears (repeat smears after smears w ithout endocervical cells and other 
unsatisfactory smears, repeat smears after 'borderline' results and follow-up smears in 
referred and treated women).
The incidence of cervical cancer in the Netherlands is -8 per 100.000 women. Around 
700 new cases of cervical cancer are diagnosed each year, and 200 wom en die as a 
result of the disease.25 About half of all wom en with new ly diagnosed invasive cervical 
cancer never participated in any screening programme.24 26 28 Cervical cancer is mostly 
diagnosed in relatively young women, unlike many other forms of cancer. W om en 
between the ages of 30 and 45 belong to the main risk cohort. For the age specific 
incidence of cervical cancer in 2008, see Figure 2. The Eindhoven Registry was the 
only registry in the Netherlands who documented regional incidence rates since 1960, 
national incidence rates were recorded since 1989, see Figure 3.
14
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Figure 2 Age specific incidence of cervical cancer per 100.000 wom en in the 
Netherlands, 200835
Figure 3 Age specific incidence of cervical cancer per 100.000 wom en in the 
Netherlands, 200835
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Cervical cancer screening in other European countries
Almost all other European countries have policies or recommendations for cervical cancer 
screening. Although all policies are mainly in line with the European recommendations 
(screening wom en every 3-5 years), there is a large variation in screening intensity that 
is a consequence of these policies, see Table 1. This intensity varies from 7-16 smears 
per wom en in a lifetime, with the exception of Germany where there is a 1-year 
screening interval and over 50 smears taken in a lifetime. The 3-year coverage in 
the participating countries varies from 50 to 82% in the national programmes.34 
The use of excess smears varies strongly between countries. Excess smears add little 
to the effectiveness of the regular programme, and therefore decrease the cost- 
effectiveness of the screening activities. However, programme screening and 
opportunistic screening have the same aim: early detection and treatment of cervical 
(pre-) malignancies.
Not all data from different countries are easy to compare. For instance, the percentage 
of abnormal cytological smears within the screening programme varies from 1.5% 
to 8% between countries.34 This may reflect differences in the prevalence of 
neoplastic lesions, or differences in guidelines and cut-off points between negative 
and positive smears (between 'no follow-up required' and 'at least a repeat smear 
recommended').
Major geographical variations in cervical cancer incidence are observed, also between 
European countries. The highest cervical cancer incidence rates are seen in Eastern 
European countries including Romania, Bulgaria, Hungary, and Poland (25-40 per 
100.000). The lowest rates are seen in countries such as Italy, Switzerland, Spain, 
Finland and the Netherlands (less than 10 per 100.000).40'41
The implementation of hrHPV detection in cervical 
cancer screening
The possible etiological role of HPV in the developm ent of cervical cancer was 
discovered in the beginning of the 1980s by the group of zur Hausen 42, and later 
established by the group of Me/yer.42 In 2005, the World Health Organization indicated 
infection with HPV as the causal role in cervical cancer.44 The relative risk of wom en 
with persistent cervical hrHPV infections of developing cervical cancer is a 100- to 
300-fold increased.45 47 The sensitivity of hrHPV detection in identifying wom en with 
high-grade CIN or cervical cancer appeared to be higher than that of conventional 
cytology (-90% versus -60%), especially among wom en with ASC-US and LSIL smears, 
but the specificity was slightly lower (70-90% versus 90-100%).21'48 54 Large randomised 
controlled trials investigated the value of incorporating HPV detection in population
16
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Table 1 Recommendations for cervical cancer screening in European countries
Country Target age range 
(years)
Screening interval 
in years
Smears per women 
in a lifetime
Belgium 25-64 3 14
Denmark 23-59 3 13
Finland 30-60 5 7
France 25-65 3 14
Germany >20 1 50+
Ireland 25-60 5 8
Italy 25-64 3 14
The Netherlands 30-60 5 7
Sweden 20-59 3 14
UK (England) 20-65 3 or 5 16-10
based cervical screening programmes to improve the effectiveness of these 
programmes.55'56These studies indicated that large scale hrHPV testing in conjunction 
to cytology in the setting of population-based cervical screening programmes was 
accepted by both participating wom en and general practitioners, and yielded highly 
reproducible results. HrHPV testing had greater sensitivity than cytological screening 
to detect CIN3 or above, and hrHPV specificity was similar to the specificity of a single 
additional cytologic test indicating ASC-US or above.
Failures and pitfalls during cervical cancer screening, 
a chronological evaluation
The quality of a screening programme should be concentrated on the prevention of 
as many cervical cancer cases as possible, against the lowest possible financial and 
psychological costs. Five factors are formulated contributing to the effectiveness of 
screening 57: (1) the entire population at risk should be reached; (2) the screening test 
should detect as many (pre-)malignant lesions as possible; (3) the frequency at which 
the test is repeated should be high enough to catch fast-progressing abnormalities;
17
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(4) detected abnormalities should be adequately followed-up, and (5) the treatment 
should cure any discovered abnormalities. Unfortunately, not one single screening 
test is perfect and understandably, financial costs will always be considered.
The target age-range
Possible pitfalls in cervical cancer screening start with the selection of wom en eligible 
for screening. By setting age ranges for screening, by definition, only a proportion of 
the population at risk is reached. Although it is known that cervical cancer is mainly 
diagnosed between the ages of 30 and 60 years, the age range set in the Netherlands 
will definitively let wom en be diagnosed with cervical cancer before and after the 
target age-range, and therefore, often w ithout previous screening. Figure 4a shows a 
model in which is demonstrated that 5-yearly screening of wom en between 30 and 
60 years of age, assuming a coverage of 100%, lowers mortality by a maximum of 
80%.5 8
Initial attendance
After inviting wom en for screening, the actual participation rate is essential to bring 
about an effective prevention of cervical cancer. Non-attendance is still one of the 
most important limitations for the effectiveness of screening.31' 24 26 59 In the 
Netherlands, a maximum of cervical cancer mortality reduction of 56% can be 
achieved with the current age ranges, screening interval, and attendance rates, shown 
in Figure 4a.
Studies of non-attendees reported that non-attendees experienced more affective 
disadvantages of screening, were more insecure and afraid of smear taking, expected 
to experience more feelings of shame and were more insecure and anxious about the 
result. Furthermore, they thought that they had less risk of cervical cancer, less often 
intended to get future screening, and were more convinced that cervical cancer 
cannot be cured.60' 61 In order to motivate (Dutch) wom en to participate in the 
screening programme, they need to be convinced that the advantages of screening 
outweigh the disadvantages. Especially affective disadvantages need to be considered. 
In addition, awareness of the risk of cervical cancer and the potentials of screening 
need to be optimized. In order to improve the attendance even more, a personal 
invitation by a woman's own general practitioner achieves a higher attendance rate 
than invitation by the local health authority.40 41 Additionally, an invitation on a fixed 
date and time has shown to raise the overall attendance rate.62 
Som e studies showed that hrHPV testing allowed an earlier detection of persistent, 
therefore clinically relevant, lesions.62'64The observed earlier diagnosis means that the 
intervalsfor rescreening HPV-negative wom en might be extended. Extended intervals 
have the clear advantage of fewer screening episodes over a lifetime and may provide 
the opportunity of achieving higher coverage.
18
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Figure 4 Reduction in cervical cancer mortality (y-axis) in relation to
the sensitivity of the screening and the coverage of the target 
population (X-axis) in the Netherlands (modified from Bekkers et a l58, 
with permission)
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(A) Dark grey continues line: Ideal screening method (100% sensitivity of the combination: screening tool, 
screening interval, and the cohort to be screened); dark grey striped line: ideal line in the Netherlands with
5-yea rly screening of women between 30 and 60 years of age; dark grey dotted line, actual situation with a 
70% coverage rate (reduction mortality 56%), (B) dark grey arrow and dotted line: the reduction in mortality 
of 70% when the combined sensitivity of the screening method, interval, and target population is optimised 
to 100% due to the incorporation of hrHPV detection with a sensitivity of 100%,
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The sensitivity of the screening test
Once a wom an participates in screening, in an ideal situation all clinically relevant 
cervical abnormalities would be detected. Cytological screening has proven to be 
successful in reducing the incidence and mortality from cervical cancer.65 However, 
about 40%  of the cervical abnormalities are not detected in the first smear due to 
sampling and detection errors.66 The fact that invasive cancers do occur despite 
negative screening tests in the five years before diagnosis, suggests the need for 
studies on the effectiveness of new technologies and alternative screening policies.67 
Improvements in the technical standards for smear-taking and reading could 
potentially reduce the proportion of sampling and detection errors and thus increase 
the sensitivity of cytological screening. Sampling errors occur when abnormal cells 
are not (efficiently) collected or are not transferred to the microscopic slide. On the 
other hand, detection errors occur when abnormal cells on the Pap slide are missed 
or misinterpreted by the cytotechnologist. The most common sampling error is the 
result of inadequate sampling of the transformation zone, where most cervical lesions 
occur. To reduce sampling errors, the sampling device must perform optimally.68 
Moreover, clear instructions about the use of the device must be provided. Another 
potential solution to reduce false-negative results is the introduction of liquid-based 
cytology (LBC).®'71 W ith this technique, the cell sample is collected as in the 
conventional Pap test, but cells are immersed in a vial with preservation solution 
instead of spread on a slide. The vial is processed in the laboratory where the cells are 
dispersed, and a representative sample is transferred to a microscopic slide for 
interpretation. The result is a well-defined circular microscopic area containing a 
thinlayer of cells. Because sampled cells are fixed immediately after collection, fewer 
cellular morphologic artefacts occur. The cells on the slide are easier to interpret 
because the process reduces the amounts of obscuring material, such as blood and 
leucocytes, and deposits the well-preserved cells on the slide in a monolayer-like 
sample. Therefore, LBC results in less unsatisfactory smears, and smears that are easier 
to interpret.2,8 The two most used LBC systems are ThinPrep (Hologic Corporation, 
Marlborough, MA) and Sure Path (Tripath Imaging, Burlington, NC).To reduce detection 
error, some researchers advocate rescreening of the slides.72 Another approach to 
reduce detection error is improving the sensitivity of the initial screening step with 
computer-assisted screening. Depending on the system, automated devices help the 
cytotechnologist to identify abnormal cells on the slide or identify those slides that 
exceed a certain threshold for the likelihood of abnormal cells.72 A cytotechnologist 
subsequently reviews these slides.
Additionally, on the basis of the etiologic link between HPV and cervical cancer, and 
because HPV presence precedes abnormal cytology, testing for hrHPV is being 
considered as an alternative for cytology-based cervical cancer screening.74,75 To 
implement population-based hrHPV testing, HPV testing technologies must offer an
2 0
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optimal balance between sensitivity and specificity for the detection of high-grade 
CIN lesions.23 Especially young wom en often have transient infections, and more than 
80% of all HPV infections are cleared within a single year.76'77 The key issue in cervical 
screening is to detect hrHPV infections that are associated with or develop into 
high-grade CIN lesions and to differentiate them from transient hrHPV infections. Two 
tests, Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD) and GP5+/6+-PCR enzyme 
immunoassay have demonstrated a sensitivity of 90-95% for the detection of > CIN2 
in large prospective cohorts or randomized controlled trials.18'24' 78 81 Other HPV tests 
are approved for triage and screening purposes if these tests fulfil the criteria set by 
the Committee of Molecular Diagnostics in Pathology ('Werkgroep Moleculaire 
Diagnostiek in de Pathologie', W M DP).82
In order to increase the detection of (pre-)malignant lesions during cervical cancer 
screening, alternative methods have to be investigated, to increase the sensitivity of 
the primary screening test. HrHPV testing as primary screening test might offer that 
higher sensitivity.
Figure 4b shows that, at most, an additional reduction of 14% of cervical cancer 
mortality might be achieved with hrHPV testing, assuming an equal attendance.
Attendance at referral
After an abnormal or suspicious smears result, attendance at follow-up is crucial for 
the efficacy of the screening programme. Cytological triage of abnormal smears 
requires wom en to be re-tested at short intervals, and unfortunately, compliance is 
rarely complete.
There is often a delay in getting prompt follow-up of suspicious smears.59 Determined 
follow-up efforts such as reminder systems and improved medical records are needed 
for patients with abnormal cytologic screening or symptomatology that is persistent 
and inadequately explained. Efficient efforts in these areas might reduce the number 
of new invasive cervical cancer cases.
About 1-2% of the smears taken during the national cervical cancer screening 
programme will require referral for colposcopy to detect or rule out any pre-malignant 
or malignant change.31 Referral for colposcopy is associated with high levels of 
anxiety.83 8,5 These high levels of anxiety before colposcopy might have the adverse 
consequence of loss to follow-up.86 Therefore, reducing fear and anxiety seems to be 
of great importance to reach the greatest benefit from screening. Colposcopic 
assessment and treatment of cervical dysplasia at a single clinic visit (see and treat 
policy) might reduce anxiety and therefore, increase follow-up attendance.87
Balance between harms and benefits
Everyone who is involved in the screening process has to be aware of the psychological 
impact of screening and abnormal cytology. Many wom en complain of fear of cancer,
21
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fear of loss of reproductive ability or sexual function, fear of medical procedures and 
fear of loss of bodily integrity.88 W hen wom en are referred to the gynaecologist and 
attend their colposcopy appointment, it is important to take these emotions into 
account. Physical examination, treatment decisions, and follow-up schemes may 
partially be based on individual preferences. Unfortunately, more intensive screening 
greatly increases the need for more interventions for lesions which would never have 
developed into tumours.89 Treatment of cervical lesions, for example by loop excision, 
might induce new problems like preterm birth for wom en in the reproductive age. It 
is therefore important to prevent overtreatment of lesions that are less likely to 
progress into cancer. Though, immediate treatment of these lesions might sometimes 
be preferred instead of a conservative insecure treatment policy.
As discussed in the previous paragraphs, there are many opportunities for improvement 
at all levels of cervical cancer screening, and the follow-up that results from it. The 
limit for cervical cancer screening in the Netherlands has not been reached, and the 
guidelines for screening are currently in motion. In order to contribute to optimal 
cervical cancer prevention, we attempted to detect shortcomings of the current 
screening programme and investigated some possible interventions to improve the 
national cervical cancer screening programme and its follow-up.
2 2
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Outline of the thesis
Before searching for new interventions, it is important to gain insight into the reasons 
why cases of cervical cancer occur, and were not prevented by early detection and 
treatment of pre-malignancies during cervical cancer screening. In chapter 2 we 
described the screening history of 401 wom en with invasive cervical cancer. As long 
as cervical cancer occurs in wom en who are screened, attention must be directed 
towards minimizing false-negative smears. The normal smears within the preceding 
screening interval of five years were subsequently reviewed in order to be able to 
subdivide them into sampling and interpretation errors.
The screening programme results in many referrals for colposcopy because of 
abnormal smears. A substantial part of these smears is thought to normalize without 
any intervention, but, normalization takes time. Chapter 3 describes two different 
treatment strategies for tw o consecutive ASC-US smears, aggressive versus less 
aggressive, and compares the clinical outcome after a follow-up often  years.
High levels of anxiety and negative emotional responses are experienced by wom en 
throughout all stages of cervical cancer screening. Attention to quality of life and 
potential adverse aspects should therefore be part of the evaluation of screening 
programmes. W e performed a randomized controlled trial in which we investigated if 
providing individual targeted information on HPV, cervical pre-malignancies, and the 
colposcopic procedure decreases women's anxiety before colposcopy. These results 
are described in chapter 4.
It is important for gynaecologists and general practitioners to be aware of the 
additional risks that HPV infection and cervical pre-malignancies entail. Chapter 5 
describes the relation between HPV related vulvar cancer and cervical abnormalities, 
and gives some suggestions for clinicians to improve uptake of HPV related 
malignancies.
HrHPV testing on cervico-vaginal self-samples might increase the efficacy of popula- 
tion-based cervical screening programmes, by increasing the attendance rate and 
sensitivity of the primary screening tool. Chapter 6 and 7 report about HPV detection 
on the FTA cartridge, a solid dry carrierfor cervico-vaginal (self-) samples. We assessed 
amplification and hybridization based HPV assays, with different sensitivities. The 
results of the subsequent chapters are discussed in chapter 8 and summarized in 
chapter 9.
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CHAPTER 2
Abstract
Objective. To assess the screening history of wom en with cervical cancer, and review 
normal cervical smears in the five years preceding the diagnosis.
Methods. Cytological and histological results of 401 wom en treated for invasive 
cervical cancer between 1991-2008 at the Radboud University Nijmegen Medical 
Center, were studied. Ninety-eight normal smears within five years preceding the 
diagnosis were reviewed.
Results. O f the 401 women, 269 (67%) received at least one invitation for the cervical 
cancer screening program (NCSP). One-third fell outside the target age of the NCSP. 
Seventeen percent never responded to the invitation(s). Twenty-one percent had one 
or more normal smears within five years preceding the diagnosis. After review, only 
39% of those smears was reviewed as a normal smear.
Conclusions. Half of the wom en with cervical cancer were never screened because 
of the limited target age-range or non-attendance. Twenty-one percent had a normal 
smear within five years preceding the diagnosis of cervical cancer, caused by 
interpretation and/or sampling errors.
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Introduction
A national screening program for cervical cancer (NCSP) was introduced in the 
Netherlands in 1988. W om en between the ages 35 and 53 were invited for a cervical 
smear every three years. The NCSP was reorganized in 1996 to improve the effectiveness 
and efficiency of the screening program. Therefore, the age range of the target 
population was extended to 30-60 years, and the screening interval increased from 3 
to 5 years. From 1990 to 2006, the incidence and mortality rate for cervical cancer in 
the Netherlands decreased with 28% and 42%, respectively.13
Despite organized screening in the Netherlands, around 600 to 700 wom en are still 
diagnosed with cervical cancer annually.1 Factors influencing these numbers are the 
target age-range of the screening program, the frequency of screening, and 
non-attendance to the screening program.4 Important factors in wom en diagnosed 
with cervical cancer despite adequate screening are problems with sampling, 
interpretation, and consistent clinical follow-up.5 However, a small number of rapidly 
developing cancers (interval cancers) cannot be ruled out. The Pap smear has been a 
remarkably effective tool in cancer prevention. However, cytological smears have 
been associated with a significant rate of sampling and/or interpretation errors, 
resulting in a sensitivity of around 60-70%.6 8 False-negative results may have a great 
impact as cervical abnormalities might be missed, and therefore left untreated. Within 
normal limits (WNL) smears preceding cervical cancer and confirmed by cytological 
review may either be an indication for a sampling error or suggestive for a "rapidly 
progressive" form of cervical cancer. A study of W NL smears preceding cervical cancer 
may show to what extent improving interventions might be possible.9 
The aim of this study was to determine how many wom en diagnosed with cervical 
cancer in the Nijmegen region had been screened according to the national guidelines, 
and if screened properly, why screening did not prevent these cases?
Patients & Methods
Data collection
Between 1991 and 2008, 421 wom en were diagnosed with invasive cervical cancer 
and treated at the Radboud University Nijmegen Medical Center (RUNMC), Nijmegen, 
the Netherlands. Data concerning cervical cytology and histology were retrieved 
from the Dutch nationwide registry of histo- and cytopathology (PALGA).10 This 
database has national coverage from 1991 onwards, enclosing all surgical specimens 
and cervical smears ever taken from each patient, both by the general practitioner 
and medical specialists. Twenty patients who were initially diagnosed in a foreign 
country or had incomplete data were excluded, leaving 401 patients opt for evaluation.
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The cytological results were registered according to the diagnostic categories of 
Papanicolaou and/or KOPAC-B, which is easily translatable to The Bethesda 2001 (TBS 
2001) classification.11 Only cytological smears performed within the framework of the 
screening program were registered. Diagnostic smears leading to the diagnosis of 
cervical cancer, performed as a consequence of symptoms, were not included. 
Analysis has focused on smears within the screening program, prior to the diagnosis. 
Patient and tumor characteristics (e.g. stage/type) were obtained from the hospital 
medical records. All histological types were included in our analysis in order to 
properly evaluate the current screening program. According to the date of birth, we 
assessed whether wom en had ever been invited for the national screening program. 
W om en within the age category of the national screening program constituted our 
target group forfurther study. They had been invited at least once. W om en who were 
younger or older than the target cohorts were not further analyzed with respect to 
their screening history, as the aim of the study was to evaluate wom en who were 
eligible for cervical cancer screening.
In the collected data, wom en were scored as 'regularly screened', 'irregularly screened' 
or 'never screened'. A patient was scored as 'regularly screened' when screened 
according to the guidelines of the national screening program on cervical cancer 
(responded to all invitations of the national screening program, every five years from 
the age of 30 till 60). A deviation in screening interval of 10 percent was accepted. 
Patients were scored as 'never screened' if they never had a smear taken (non­
responders). Otherwise, patients were scored as 'irregularly screened'. This group 
responded to at least one of the invitations of the screening program but not to all, or 
the frequency and/or timing was not adequate (interval longer than 5 years).
All normal cervical smears within five years before the diagnosis of cervical cancer 
were requested from pathology laboratories around the country. All smears were 
made anonymous before sending them to two expert cytotechnologists (CTs) (M.S.P. 
and J.V.) for review. Both CTs scrutinized the smears for abnormal cells with full 
knowledge of the study, using a review protocol, noting the KOPAC-B classification, 
the quantity and nature of the cells, and the extent of certainty about their judgment.12 
The aim was not to repeat a normal screening setting, but to scrutinize the smears for 
abnormal cells in order to distinguish interpretation errors from sampling errors/ 
progressive forms of cancer. After an extensive search for abnormal cells, all cervical 
smears were provided with a new diagnosis, according to the 2001 Bethesda System.11 
In case the judgm ents of the two CTs were discordant, they reassessed the smear 
together and came to concordance.
Statistical analyses
The Statistical Package for Social Sciences (SPSS version 16.0) was used to perform 
the analyses. Patient characteristics and tumour characteristics were compared using
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non parametrical tests (Chi-square and Mann-Whitney). We considered p < 0.05 as 
statistical significant.
The study was exempt from Institutional Review Board approval because data were 
gathered retrospectively and subsequently made anonymous.
Results
O f the 401 eligible women, 269 (67%) had been at least once invited for participation 
in the national screening program ("target cohorts"). A number of 87 wom en (22%) 
exceeded the age limit to be invited for the NCSP ("older than target cohorts") and 45 
(11%) were younger than the starting age of the NCSP when diagnosed with cervical 
cancer ("younger than target cohorts"), see the flow  diagram in Figure 1. The youngest 
group showed 36% non-squamous cell carcinoma's compared to 16% of the oldest 
group (p=0.011). The non-squamous cell carcinoma's in the youngest group mainly 
consisted of adenocarcinoma's. They counted for 26.7% of the total carcinoma's in the 
youngest group, compared to 19.7% in the target cohort and 11.5% in the oldest 
group. In the oldest group, 54% had advanced stage (> MB) disease, compared to 18% 
in the youngest and 11% in the target group, (pcO.OOl). W om en of the target cohort 
who were regularly screened had in 13.1% stage 1A disease versus 7.4% for those who 
were irregularly screened. This difference was not statistically significant (p=0.123). 
Patient and tumor characteristics are shown in Table 1.
O f the 269 wom en of the target cohorts, 107 (40%) were screened according to the 
guidelines of NCSP (cytological smear every five years from the age of 30 till 60). Of 
the remaining invited patients, 68 (25%) were never screened (non-responders) and 
94 (35%) were irregularly screened, see Figure 1. O f the 107 regularly screened women, 
36 were diagnosed with cervical cancer when they responded to their first invitation 
for cervical screening.
O f the 201 wom en who ever participated in the NCSP, 85 (42%) had at least one normal 
cervical smear within the five years before the diagnosis of cervical cancer, and 
therefore, within the screening interval. Because some wom en had more than one 
normal smear within the interval, these 85 wom en had a total of 136 normal smears 
preceding the diagnosis. O f these smears, 105 (77%) were retrieved from 17 different 
pathology laboratories. The other 31 smears were not retrieved because one pathology 
laboratory denied collaboration, because the smears were older than the restricted 
storage period often years and therefore destroyed, or they were not traceable. Seven 
AutoCyte PREP' smears (BD diagnostics/Tripath, Inc., Burlington, USA) were excluded 
because the selected CTs lacked experience with this method and the selection of a 
third CT would not contribute to the equality of the study. Of the remaining 98 smears,
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Figure 1 Flow diagram of total 401 women with invasive cervical cancer at
the RUNMC in the period 1991-2008, including reviews of the normal 
smears within five years before the diagnosis
20
Immigrants excluded
45 (11%) 
Younger than target cohort
87 (22%)
Older than target cohort
85/201 (42%) 
WNL smear < 5yrs 
before diagnosis
----1/
Review: 
19% > HSIL
Review: Review: Review:
24% unsatisfactory 39% WNL 18% ASCUS/LSIL
87 (89%) were conventional smears and 11 (11%) were liquid based smears (Thin prep, 
Hologic, Inc., Marlborough, USA). In total, 38 (39%) smears were considered to be 
normal after review and 23 (24%) were judged as unsatisfactory for evaluation. Reasons 
for unsatisfactory smears were few epithelial cells, too many leucocytes, and too 
much blood, or a combination of these. These smears were initially incorrectly
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classified as W NL instead of repeated after six weeks. In total, 18 (18%) smears were 
reviewed as atypical squamous cells of undetermined significance (ASC-US) or 
low-grade squamous intraepithelial lesion (LSIL). These wom en would otherwise have 
been advised to have a repeat smear in six months. Nineteen smears were reviewed 
as high-grade squamous intraepithelial lesion (HSIL) or more severe, and should 
therefore have been referred to the gynaecologist immediately. For the review results, 
see table 2 and 3.
Table 2 Review of within normal limits cervical smears within five years before 
the diagnosis of cervical cancer
Review Liquid Basedn (%)
Conventional
n (%)
Total
n (%)
Unsatisfactory smear 2(18%) 21 (24%) 23 (24%)
W N L smear 7 (64%) 31 (36%) 38 (39%)
ASC-US/LSIL smear 2(18%) 16(18%) 18(18%)
> HSIL smear 0 19(22%) 19(19%)
Total 11 (100%) 87(100%) 98(100%)
WNL, within normal limits; ASCUS, atypical squamous cells of undetermined significance;
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion
W hen the total 401 wom en with cervical cancer were considered, 33% was diagnosed 
outside the target age range of the NCSP, and 17% never responded to the invitation 
of the NCSP. These wom en were never screened. Another 17% was screened, but the 
last smear before the diagnosis of cervical cancer exceeded the screening interval of 
five years. Thirteen percent was incorrectly diagnosed with a normal smear within five 
years preceding the diagnosis of cervical cancer. Eight percent had a normal smear 
(confirmed by review), suggesting a sampling error or a rapidly progressive tumour. 
The remaining 12% were either diagnosed when they attended their first screening 
round (9%) or developed cervical cancer despite follow-up of abnormal smears, by 
cytology and/or colposcopy (3%), see Figure 2. It was not possible to trace where 
appropriate follow-up, evaluation (e.g. colposcopy) or treatment (e.g. LEEP, cone 
biopsy or cryotherapy) went wrong. It was estimated that these follow-up smears 
were either misinterpreted, or colposcopic evaluation was insufficient.
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Table 3 Unsatisfactory smears previously diagnosed as within normal limits 
(WNL) smears
reasons for unsatisfactory smears unsatisfactory smears (n)
A (too much blood) 1
B (too many leucocytes) 6
C (few epithelial cells) 8
D (badly fixated) 1
A+B 1
A+C 2
B+C 3
A+B+C 1
Total 23
Figure 3 Diagram of the total 401 wom en with cervical cancer, subdivided into 
categories of explanations why screening did not prevent these cases
3 %
■ 33% outside target age range
^ 9% diagnosed after first screening round 
(too-late initiating screening)
h  17% non-responders
■ 17% screened, but last smear 
> 5yrs before diagnosis
H 13% interpretation error 
(unsatisfactory smear/> ASCUS smear)
^ 8% sampling error/progressive tumor 
(WNL smear)
U 3% cervical cancer despite intensive 
follow-up by cytology/colposcopy
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Discussion
This relatively large study, from a centrally organized program, with a pathology 
database that has full national coverage makes these data useful alongside other 
studies.1315 This study shows that 33% of wom en with cervical cancer are diagnosed 
outside the target age range of the NCSP. Additionally, 17% of the patients within the 
target age range never responded to any of the invitations. Therefore, half of the 
wom en were never screened before the diagnosis of cervical cancer. An additional 
9%  was diagnosed after responding to the invitation of their first screening round. 
Seventeen percent was at least ones screened, but had their last smear longer than 
five years before the diagnosis of cervical cancer. Twenty-one percent had a normal 
smear preceding the diagnosis of cervical cancer, suggesting an interpretation or 
sampling error, or a combination of those.
O f the 401 wom en included in this study, 45 (11%) and 87 (22%) wom en were 
respectively younger or older than the target cohorts to be invited for cervical cancer 
screening. Another 9%, diagnosed after their first invitation, was due to too-late 
initiation of screening. This is in accordance with the study of Bos et a I.16, in which they 
describe that in the Netherlands around 30% of the wom en with cervical cancer never 
had been invited for cervical cancer screening because of their age. However, the 
proportion of wom en older than the target cohort will be reduced in the future, 
because this cohort will vanish in time. In the Netherlands, the age range (30 to 60 
years) is rather limited as compared to other countries where some screening 
programs start inviting at the age of 20 and continue till the age of 65.17 Extending the 
age range may lead to better prevention of cervical cancer and to earlier diagnoses of 
earlier stage of disease. However, despite extending the age range, there is still a risk 
of missing adenocarcinomas in the youngest group, as the sensitivity of cervical 
cytology for the detection of adenocarcinomas is significantly lower than that for 
squamous carcinomas.1821
Despite the NCSP with 5-yea rly invitations, 25% of the invited patients never responded 
to any of the invitations before they were diagnosed with cervical cancer. Another 
35% of the wom en responded to at least one of the invitations, but not to all or not in 
time. This stresses the fact that, in accordance with previous studies162227, 
underscreening is the most important modifiable risk factor for cervical cancer. 
Nonattendance has been reported previously as being due to fear, embarrassment, a 
male doctor and having a too busy schedule.28 Efforts should be undertaken to 
increase the coverage of screening.29
Consistent with previous studies, we found a substantial number of wom en with a 
W N L smear preceding the diagnosis cervical cancer.2226 The fact that cervical cancer 
can occur despite a history of regular screening, suggests the need for further studies 
of primary screening tests.22 According to the reviews of the W NL smears in this study,
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38% indicated interpretation errors. Another 39% of the smears was confirmed W NL 
by review and suggestive for sampling errors, or a fast carcinogenesis (rapidly 
progressive cancer) after the smear was taken. Non-squamous cancers might be those 
rapidly progressive cancers, and are often located in the endocervix. These 
non-squamous cancers are therefore not easily detected by cytological screening. 
The percentage of non-squamous cancers was slightly higher (34%) in the group of 
wom en with a W N L smear within five years preceding the diagnosis of cervical cancer, 
compared to the total group (22.7%). Remarkably, one fourth of the reviewed smears 
was unsatisfactory for evaluation. The cervical lesion might have been detected if 
these smears would have been repeated after six weeks, according to the guidelines. 
The majority (89%) of these unsatisfactory smears were conventional smears. This 
might suggest that conventional smears are more likely to be unsatisfactory than 
liquid based cytology, as previously reported.30 31 However, this suggestion completely 
depends on the distribution of conventional smears versus liquid based smears in the 
screening population. During the study period, the use of solely conventional cytology 
slowly shifted towards a combination of conventional and liquid based methods.
The sensitivity of cytology for the detection of cervical lesions may be increased by 
improving the technical standards for smears and their reading.5-32 35 Recently, it has 
been shown that improving the sensitivity of the initial screening step by using an 
additional hr-HPV test, might further reduce the proportion of false-negative 
results.7'36 -37 The non-squamous cervical cancers in this study, which were mainly ad­
enocarcinomas, are as well detectable by hrHPV testing. Additionally, cervico-vaginal 
self-samples appear to be as reliable as physician taken samples.38'39 Screening by 
self-samples performed in the privacy of woman's own homes, might provide a better 
attendance than screening by samples taken by physician or other health care 
providers.4041 A self-sampling method for hrHPV performed by the wom en herself, 
might be a possible way for current non-responders to lower the threshold to attend, 
and increase the coverage of screening.4042 Although hrHPV testing has a higher 
sensitivity than cytological screening to detect cervical abnormalities, it has a lower 
specificity. It is important to search for a balance between harms and benefits. Triage 
strategies for wom en who are hrHPV positive, for example by repeat hrHPV testing, 
subsequent cytology, or the use of biomarkers, increases specificity and prevents 
overtreatment.
However, concerning this study, we have to consider that the NCSP started in 1988 
and wom en diagnosed just after the beginning of the national program could not 
have optimally benefitted from screening. After all, the sensitivity of the screening 
program is higher due to a repetition of a moderate sensitive test. Furthermore, the 
CTs reviewed all smears with full knowledge of the study. The purpose of this study 
was to scrutinize the smears for abnormal cells, in order to distinguish interpretation 
errors, sampling errors or progressive forms of cancer. The aim was not to repeat a
41
C H A PT ER  2
normal screening setting. Therefore, the sensitivity of the detection of abnormal 
smears in this study is not completely comparable with that in a screening setting.12 
A limitation of this study is that the study population is drawn from a single medical 
centre. Though, the RUNMC renders referral medical services for 1.500.000 people, 
and therefore practically reflects the general population. A long inclusion period is 
required to achieve a large cohort in a single centre. However, this study does provide 
us the opportunity to detect where improvements are achievable in this chain of 
events, and which part of the cervical cancer incidence is attributable to limited 
detection of (pre-) malignancies of cervical cancer. Another limitation is that wom en 
with cervical cancer stage IA are not necessarily referred to the RUNMC and often 
treated at regional hospitals, as a result of which our study population contains 
relatively less stage IA cervical cancers. Additionally, the RUNMC is a national referral 
centre for radical trachelectom y for small stage IBI cervical cancers. A maximum of 30 
wom en were referred with this indication during the study period.
In conclusion, new cases of cervical cancer occur due to 1) nonattendance to the 
NCSP, 2) a narrow target age range of 30 to 60 years, and 3) limited sensitivity of the 
screening test caused by sampling and/or interpretation errors. Therefore, the target 
age-range of the current NCSP in the Netherlands may need to be re-evaluated, and 
shortening the screening interval might decrease the percentage of W NL smears 
before the diagnosis of cervical cancer. The incidence and mortality rate from cervical 
cancer can be reduced further by interventions to increase the participation rate of 
the NCSP and by improving the sensitivity of the screening test. Using additional 
hr-HPV testing and/or hrHPV self-sampling for non-responders are possibilities to 
reach this goal.41
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CHAPTER 3
Abstract
Introduction. Managem ent of patients diagnosed on cervical smears with twice 
consecutively atypical squamous cells of undetermined significance (ASC-US) cervical 
smears remains a clinical dilemma. We describe an observational study of a follow-up 
of 10 years of aggressive versus less aggressive colposcopic treatment in order to 
determine which treatment is preferable.
Methods. We performed a retrospective cohort study of two hospitals in the 
Netherlands with different colposcopic treatment strategies. A total of 230 patients 
referred for primary colposcopy because of two consecutive ASC-US smears to either 
one of the tw o hospitals were evaluated regarding a follow-up period of 125 months. 
One-hundred-eighteen patients underwent direct loop excision of all colposcopically 
detected abnormalities, even if not suspected for CIN (aggressive strategy). In 112 
patients a less aggressive policy was followed in case low grade cervical intraepithe- 
lial neoplasia (CIN) lesions were suspected at colposcopy (less aggressive strategy). 
The number of loop excisions, detection of CIN lesions and cytological follow-up of 
both groups were analyzed to develop an optimal treatment strategy for patients 
with two ASC-US smears
Results. Less aggressive management resulted in less loop excisions (pcO.OOl). At 
initial colposcopy, the aggressive group showed a tenfold of histologically detected 
CIN lesions compared to the less aggressive group (1.8% versus 19.5%). During ten 
years of follow-up, both groups showed the same percentages of CIN lesions (8.1% 
versus 8.4%). Aggressive management resulted in faster normalization of cervical 
smears (pcO.OOl). However, at 125 months follow-up, there was no statistical difference 
in the percentage of normalization of cervical smears between both groups. 
Conclusions. The aggressive and less aggressive colposcopic strategies are equally 
safe and show good clinical outcomes. Treatment decisions, however, must be 
adjusted to women's individual demands.
TO TREAT OR NOT TO TREAT, THE CLINICAL DILEMMA OF ASC-US
Introduction
The optimal treatment strategy for patients diagnosed with atypical squamous cells of 
undetermined significance (ASC-US) remains controversial. There are three strategies 
suggested; immediate colposcopy, triage to colposcopy based on human papilloma­
virus (HPV) detection, or triage based on repeated cytology.1 Since 1996, the triage 
strategy used in the Netherlands is a repeat smear after six months. In 2006, high risk 
(hr) HPV testing has been incorporated in the triage strategy. Both triage strategies will 
reduce the number of women referred for colposcopy and, therefore, increase the 
probability of detecting abnormalities during colposcopies. In the Dutch 5-yearly 
screening program starting at 30 years, 2.5% of cervical smears are graded as ASC-US or 
low-grade squamous intraepithelial lesion (LSIL).- About 32% of the patients diagnosed 
with primary ASC-US, still have an ASC-US or a higher grade lesion during follow-up.3 
This results in referral for colposcopic evaluation.
Despite either of these triage strategies, a group with a low risk of developing high-grade 
lesions will remain. It is estimated that 15% of patients diagnosed with an ASC-US smear 
and referred for colposcopy will develop a cervical intraepithelial neoplasia (CIN) lesion 
grade 2 or 3 within 24 months.4 No national colposcopic guidelines existed. Hence, 
management during initial colposcopy was either by excision of all abnormalities seen 
by colposcopy, or by excision of only abnormalities suspect for high-grade lesions.5 7 
The risk of developing invasive cancer, if untreated, is estimated to be 1% in patients 
with CIN 1, 5% in patients with CIN 2, and 15% in patients with CIN 3 lesions.810 The 
majority of CIN lesions regress in time and do not require treatment. Thus, both low 
specificity of colposcopy following an ASC-US or LSIL smear and low risk of progression 
of CIN lesions to invasive cancer may lead to overtreatment.
In this study, we investigated ten years of follow-up of patients referred with two 
consecutive ASC-US smears with a six month interval. An aggressive colposcopic 
management strategy was compared with a less aggressive colposcopic management 
strategy, to determine which strategy is preferable.
Material and methods
Between April 1997 and December 1999, 295 patients from the Nijmegen region were 
referred to the gynaecologic departments of the Radboud University Nijmegen 
Medical Centre (RUNMC) or the Canisius Wilhelm ina Hospital Nijmegen (CWZ), the 
Netherlands, with two consecutive ASC-US smears during the national screening 
program. In retrospect, only 252 of these patients had tw o consecutive ASC-US smears 
within the six month interval. The two hospitals used different ASC-US m anagement 
strategies, either aggressive or less aggressive. Referral to one of the hospitals was
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decided by the referring general practitioner w ithout knowledge of this difference in 
treatment strategy Twenty-two patients were excluded because of the following 
factors: a duration longer than 12 months between referral and colposcopy (n=5); 
hysterectomy during follow-up for reasons other than (pre)neoplastic lesions (n=9); 
and a follow-up period of less than 24 months (n=8). The remaining 230 patients were 
included; 112 patients were referred to the RUNMC and 118 patients were referred to 
the CWZ. Data concerning cervical cytology and histology were retrieved from PALGA, 
the nationwide Netherlands database of histo- and cytopathology. This database has 
national coverage from 1991 onwards, revealing all surgical specimens and cervical 
smears ever taken from each patient, both by general practitioners and medical 
specialists.11 Therefore, all 230 patients could be included in the analyses. In order to 
provide a good reflection of the current screening, the cytological smears were not 
reviewed apart from the regular quality controls used in the screening program.
Management strategies
Colposcopy was performed within one month of intake consultation in all 230 
patients. Patients referred to the RUNMC were seen by one of the three colposcopists, 
and only lesions suspected for CIN 3 were treated with a colposcopically directed 
loop electrosurgical excision procedure (LEEP) on the basis of a 'see and treat' policy 
(less aggressive management strategy). A 'see and treat policy' has been adopted in 
many Dutch hospitals, consisting of a colposcopic examination combined with a LEEP 
in all patients with colposcopically suspect lesions. Diagnosis and therapy are 
combined with this policy.12 Patients referred to the CW Z were seen by one of the six 
colposcopists and underwent a colposcopically directed LEEP of every abnormality 
seen at colposcopy, independent of the suspected grade (aggressive management 
strategy). Cytological follow-up after colposcopy was identical in both hospitals, 
following the national guidelines of performing a smear after 6, 12 and 24 months. 
Colposcopy was repeated in case of an ASC-US smear or worse.
Aggressive versus less aggressive management strategy
The two groups were compared with respect to age at referral, mean duration of 
follow-up, number of performed LEEPs, and number of different grades ofC IN lesions. 
Histo-pathological examination of the excised material was performed by an 
experienced gynaeco-pathologist in both hospitals. For this study, the first 36 months 
represent the short-term follow-up (3 yrs), as previously published by our study 
group12, and the total 125 months represent the long-term follow-up (approximately 
10 yrs). Cytological results were analyzed regarding two different properties. First, the 
normalization of cervical smears was analyzed. Smears were considered to be 
normalized when a patient had two consecutive normal smears. Second, the total 
number of smears performed during follow-up was analyzed.
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Statistical analyses
All statistical analyses were performed using SPSS 16.0 (Statistical Package for the 
Social Sciences Benelux BV, Gorinchem). All statistical analyses were performed using 
the independent samples (student-t) test. Differences with a p-value less than 0.05 
were considered significant.
Results
There was no significant difference between mean age of patients from the less 
aggressive (n=112, mean 45 yrs, range 30 - 60) or the aggressive group (n=118, mean 
46 yrs, range 30 - 61). Mean duration of follow-up was 125 months (range 32 -134). Two 
patients of the less aggressive group had a hysterectomy performed as a consequence 
of a uterine prolaps, in combination with abnormal cervical cytology. These 
hysterectomies were performed after a follow-up period of 55 and 92 months. One 
patient of the aggressive group had a hysterectomy after a follow-up period of 92 
months, performed as a consequence of meno- and metrorrhagia, in combination 
with abnormal cervical cytology. During follow-up, two patients of the aggressive 
group died of causes unrelated to cervical pathology.
The less aggressive treatment group
At initial colposcopy, in 7.1% of the cases in the less aggressive group, a LEEP was 
performed (n=8). During follow-up, the percentage of LEEPs performed was 25.1 (n=28). 
The 36 histology results in the less aggressive group were derived from 34 specimens 
collected by a LEEP and two specimens by hysterectomy. Five patients had more than 
one LEEP during follow-up. Examination of the surgical specimens taken at initial 
colposcopy in the less aggressive group, revealed six normal tissues ("no CIN", 5.3%), 
one "ClN 1" lesion (0.9%) and one "CIN 2" (0.9%) lesion. Analyses of the histological 
specimens taken during follow-up revealed 17 normal tissues ("no CIN", 15.2%), five "CIN 
1" lesions (4.5%), two "CIN 2" lesions (1.8%) and two "CIN 3" lesions (1.8%). Two biopsies 
(1.8%) could not be interpreted due to insufficient quality of the specimens (Table 1). 
Cytological follow-up was evaluated regarding two aspects; percentage of normalized 
smears and number of smears per patient (Table 2). During the first 36 months of 
follow-up, 36.6% of the smears normalized. During the 125 months of follow-up, 92% of 
the smears normalized. All women whose cervical smears did not normalize had 
alternately normal and ASC-US smears during follow-up, although never two consecutive 
normal smears. The number of performed cervical smears during follow-up was also 
evaluated. In the first 36 months of follow-up, the mean number of performed smears 
per patients was 2.7. During the follow-up period of 125 months, the number of cervical 
smears per patient in the less aggressive group was 6.0 (Table 2).
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Table 1 Biopsies taken at initial colposcopy and the most severe histological
result of each patient during follow-up (125 months) of patients managed 
with a less aggressive strategy (n=112) or an aggressive strategy (n=118) 
because of two consecutive ASCUS smears
Less aggressive group Aggressive group
Initial Follow-up Initial Follow-up
%  (n) %  (n) %  (n) %  (n)
NoCIN 5.3 (6) 15.2(17) 63.5 (75) 16.9 (20)
CIN 1 0.9(1) 4.5 (5) 12.7 (15) 6.8 (8)
CIN 2 0.9(1) 1.8 (2) 5.1 (6) 0.8(1)
CIN3 0 1.8 (2) 1.7 (2) 0.8(1)
Not Interpretable 0 1.8 (2) 5.1 (6) 0
Total 7.1 (8)a 25.1 (28)b 88.1 (104)a 25.3 (30)b
CIN, cervical intraepithelial neoplasia 
ap<0,001
bno significant difference
Table 2 Percentage of patients with normalized smears and number
of performed smears per patient, in patients managed with a less 
aggressive strategy (n =112) or an aggressive strategy (n =118) in 
36 and 125 months follow-up
Less aggressive 
group
Aggressive group
36 months follow-up
%  normalized smears (n) 36.6 (41)a 69.5 (82)a
Number of smears per patient (total n) 2.7 (299)b 2.8 (326)b
125 months follow-up
%  normalized smears (n) 92.0 (103)b 94.1 (111)b
Number of smears per patient (total n) 6.0 (674)c 5.3 (619)c
a pcO.OOl
bno significant difference 
c p=0,043
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The aggressive treatment group
At initial colposcopy, a LEEP was performed for 88.1% of the patients of the aggressive 
group (n=104). During follow-up, 25.3% of the patients underwent a LEEP (n=30). 
There were 134 histology results, consisting of 133 specimens collected trough a LEEP 
and one specimen from hysterectomy. Six patients had more than one LEEP during 
follow-up. In the aggressive group these histological specimens revealed 75 normal 
tissues ("no CIN", 63.5%), 15 times a "ClN 1" lesion (12.7%), six times a "ClN 2" lesion 
(5.1%) and two "ClN 3" (1.7%) lesions. Six biopsies (5.1%) taken in the aggressive group 
could not be interpreted. Analysis of the most severe histological finding per woman, 
taken during follow-up of the aggressive group, revealed 20 times normal tissues ("no 
CIN", 16.9%), eight times a "CIN 1" lesion (6.8%), one "ClN 2" lesion (0.8%) and one "ClN 
3" lesion (0.8%) (Table 1). During the first 36 months of follow-up, 69.5% of the cervical 
smears normalized. In 125 months offollow-up, however, 94.1% of the cervical smears 
normalized. Again, the smears qualified as not normalized, had alternately normal and 
ASC-US smears during follow-up, although never two consecutive normal smears. In 
the first 36 months offollow-up, the mean number of performed smears per patients 
was 2.8. During the follow-up period of 125 months, the number of cervical smears 
per patient in the aggressive group was 5.3 (Table 2).
The comparison
With aggressive management at initial colposcopy, during 88.1% of all colposcopies, a 
LEEP was performed. This was a ten times the number of LEEPs performed with less 
aggressive management (7.1%). During this initial aggressive management, there were
23 (19.5%) CIN lesions detected, compared with only two (1.8%) CIN lesions in the 
initial lessaggressive managementgroup. During long-termfollow-up, the percentage 
of LEEPs performed in the less aggressive versus aggressive group were comparable, 
25.1% versus 25.3%, respectively. Furthermore, the number of CIN lesions detected 
during long-term follow up did not differ between both groups. The less aggressive 
management group revealed 8.1% (n=9) CIN lesions compared with 8.5% (n=10) CIN 
lesions intheaggressive management group (Table 1). However, there w asa significant 
difference according to normalization of cervical smears. In the less aggressive group, 
36.6% of the smears were normalized within 36 months compared with 69.5% of the 
smears in the aggressive group. After 125 months offollow-up, there was no statistical 
difference between normalization of smears, i.e. 92.0% of the smears in the less 
aggressive group were normalized compared with 94.1% in the aggressive group. The 
number of smears that were performed during the first 36 months was equal in the 
less aggressive and aggressive groups, but differed during the long-term follow-up 
(respectively 6.6 versus 5.3, p=0.043) (Table 2).
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Discussion
Optimal management of patients diagnosed with ASC-US is still a matter of debate. 
Our group previously discussed a short-term follow-up of less aggressive versus 
aggressive management of ASC-US smears in the Dutch screening program; no 
difference in outcome was detected between primarily aggressive or less aggressive 
management of patients referred with two consecutive ASC-US smears.13 However, a 
large difference of primary detected CIN lesions between the tw o groups was found. 
Due to the short-term follow-up, it remained unclear whether these CIN lesions, 
"missed" during the less aggressive strategy, may lead to a higher incidence of CIN 2-3 
or invasive cervical cancer during follow-up, or whether these lesions regress in time. 
This study confirmed that patients referred on the basis of two consecutive ASC-US 
smears by the screening program may be safely managed with a less aggressive 
colposcopic strategy. Even during ten years of follow-up, no increased risk of 
developing CIN 2-3 or cervical carcinoma after less aggressive management was 
shown.
These data may suggest that several CIN lesions were missed with less aggressive 
management at initial colposcopy. However, it could confirm that most lesions 
(particularly CIN 1), do regress in time and do not require immediate treatment.14' 15 
In this study, less aggressive treatment revealed 68% less CIN 1 lesions than aggressive 
treatment (6.6% vs 19.5%). Although the number of initial CIN 2-3 lesions in the less 
aggressive treatment group is less than that in the aggressive treatment group, none 
of the wom en in the study group developed invasive cervical cancer within the ten 
years of follow-up. Thus, it appears that "undetected "CIN lesions at primary colposcopy 
in the less aggressive treatment group either regressed or they were detected during 
follow-up.
After aggressive management, more cervical smears normalized within 36 months of 
follow-up. Thus, it appears that an initial colposcopically directed LEEP in patients 
diagnosed with two consecutive ASC-US smears, independent of presence orabsence 
of a CIN lesion, leads to faster normalization of cervical smears than w ithout a LEEP. 
After a follow-up period of 125 months, however, there was no difference in 
normalization of cervical smears between both groups. In other words, initial fast 
normalization of follow-up smears with aggressive management did not show any 
long-term advantage versus less aggressive management with respect to the risk of 
developing cervical cancer. However, aggressive treatment with faster normalization 
may take away women's concerns, and therefore, may in some cases be preferred. 
Initial less aggressive management proved to be less invasive during long-term 
follow-up. Less aggressive management resulted in significantly less LEEPs at the 
initial colposcopy. Moreover, no significant difference was found in the number of 
performed LEEPs during follow-up. Owing to the high number of LEEPs in the
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aggressive group during first colposcopy, we expected the number of LEEPs during 
follow-up to be less than that of the less aggressive group. The management strategy 
during initial colposcopy appeared to be of no influence on the number of LEEPs 
performed during follow-up.
In contrast, less aggressive management resulted in more smears taken during the 
125 months of follow-up. This difference of cervical smears per patient may be 
explained by a slower normalization of cervical smears, and is a logical result of a less 
aggressive strategy with follow-up by means of cytology. On average, less than one 
extra cervical smear was performed during 125 months of follow-up. In some cases, 
this safe, less aggressive management may be preferred ato invasive treatment, for 
instance in the young age group who may wish to bear children in future.
Triage with hrHPV testing has been incorporated in the Dutch screening program 
since 2006. W hen a first ASC-US smear is obtained, a second smear is advised after 6 
months. Additional hrHPV testing is advised for this repeat smear. Only when an hrHPV 
positive repeat ASC-US smear is found, will the woman concerned be referred to the 
gynaecologist for colposcopy. According to this hrHPV triage system, another 
reduction of wom en referred for colposcopy is obtained. W ith this strategy, we expect 
the same number of patients with high-grade cervical lesions during less colposcopies. 
This strategy will probably lead to a higher prevalence of high-grade cervical lesions 
during colposcopy. However, in our opinion, even after this hrHPV triage, still, a 
m inority of patients will harbour CIN 2-3 lesions.16' 17 This may still justify a less 
aggressive colposcopic management.
As the national screening program in the Netherlands invites all wom en 5-yearly 
starting at age 30, there were no patients under this age included. The mean age of 
wom en with ASC-US was higher than the mean age reported in other studies.1'18 The 
mean age of the detection of wom en with ASC-US smears appears to be dependent 
on the onset of screening. However, since clearance of hrHPV infections and regression 
of CIN lesions is mostly seen in younger women, the regression seen in this population 
may not be attributable to this age difference. This regression may be of even more 
importance in a younger age group.
There are several reasons to prefer aggressive management above less aggressive 
management or vice versa. An aggressive management may be preferred despite the 
possible negative consequences of invasive treatment, iffast normalization isfavoured; 
because of the uncertainty of adequate follow-up, because of an active child wish, or 
because of psychological issues. Less aggressive management may be preferred 
because of the non-invasivity. All excisional procedures used to treat cervical intra- 
epithelial neoplasia seem to be associated with adverse obstetric morbidity, such 
as preterm delivery, low birth weight, and premature rupture of membranes.1922 
The risks increase with increasing excision depth and volume.19 Therefore, wom en of 
a reproductive age should be counselled about the potential impact on future
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pregnancies. This lends support to the philosophy not to treat young wom en with 
mild abnormalities. Adequate quality of colposcopic follow-up is necessary to 
guarantee a safe less aggressive management.
A 'see and treat policy', as has been adopted in many Dutch hospitals, reduces the 
number of colposcopic examinations in women, and is an inexpensive, effective, 
rapid and safe technique.23 However, this policy carries the risk of unnecessary 
treatment, especially when performed by an inexperienced colposcopist. In order to 
reduce the possible negative consequences of invasive treatment, a preceding 
evaluation of the seriousness of the cervical lesion by means of punch biopsies might 
be considered. However, colposcopy with punch biopsies in detecting high-grade 
CIN shows varying degrees of correlation (50-80%).2425
In conclusion, colposcopic management of patients with two consecutive ASC-US 
smears may either be less aggressive or aggressive. Both strategies are equally safe 
and show good clinical outcomes. Less aggressive colposcopic management may 
result in 80% less LEEPs and allows spontaneous regression of most low grade (pre) 
neoplastic lesions (particularly CIN 1), but takes more time to reach normalization. If a 
faster normalization is required because of psychological issues, an active desire to 
bear children or uncertainty of adequate follow-up, aggressive management may be 
preferred. Even after the introduction of hrHPV triage, there is no further need for 
aggressive management provided that adequate follow-up can be guaranteed.
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CHAPTER 4
Abstract
Introduction. W om en experience high levels of anxiety and negative emotional 
responses at all stages of cervical screening. W e conducted a randomized controlled 
trial to see whether providing targeted information on an individual level reduces 
anxiety in wom en referred to the colposcopy clinic.
Methods. Between December 2007 and April 2010,169 patients with abnormal smear 
results were randomised into two study arms. Group A received individually targeted 
information about the diagnosis and procedure by mail and phone. Group B only 
received the standard folder about colposcopies alone. Patients were requested to fill 
out a questionnaire prior to their first colposcopy appointment. Questionnaires 
included the Hospital Anxiety and Depression scale (HADS), and the Spielberger State 
and Trait Anxiety Inventory (STAI), as well as a short self-administered questionnaire. 
Results. Twenty wom en were excluded from further analyses after randomisation, 
leaving 149 wom en for evaluation. The median STAI state anxiety score was high 
(50.0), but there was no significant difference in median STAI state anxiety and HADS 
anxiety scores between both groups. However, knowledge about human 
papillomavirus and the colposcopy procedure did significantly increase in group A 
(p=0.004).
Conclusion.
Anxiety levels before primary colposcopy are surprisingly high and are not decreased 
following individually targeted information given before colposcopy.
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Introduction
About 1-2% of the cervical smears taken during the national screening program will 
require referral for colposcopy to detect or rule out any pre-malignant or malignant 
change.1 A large proportion of the referred wom en will be diagnosed with a 
premalignant lesion. Women experience high levels of anxiety and negative emotional 
responses at all stages of cervical screening. Many wom en have poor knowledge 
and understanding of cervical cancer screening, subsequent treatment, and the 
significance of the results. They often th inkthe purpose of the test is to detect cancer 
rather than to prevent it. Apart from the fear of having cancer, they have concerns 
about reproduction.2 Relatively few studies of cervical screening have included 
psychological costs, yet mass screening programs have the potential to do harm as 
well as good.2 Moreover, insensitive notification of abnormal screening results can 
add to a patient's distress.4 High levels of anxiety before and during colposcopy can 
have adverse consequences, including pain and discomfort during the procedure and 
subsequently may result in defaulting follow-up.
A 'see and treat' procedure during colposcopy, where visual inspection of the cervix 
and immediate therapy by means of loop excision are combined, are performed on a 
regular basis throughout the East of the Netherlands. W om en undergoing such a 'see 
and treat' procedure during colposcopy, experience higher anxiety levels compared 
to new patients for only diagnostic colposcopy.5'5 However, colposcopic 'see and treat' 
management, in terms of total anxiety, may ultimately be psychologically beneficial.7 
In order to reach the greatest benefit from the screening program, it seems to be 
important to decrease fear and anxiety.810 Our group previously reported that wom en 
referred for colposcopy, who considered the level of information provided by the 
general practitioner or gynaecologist insufficient, had significantly higher anxiety 
scores.11 This study was conducted to see whether providing targeted information on 
an individual level reduces fear and anxiety in wom en with an abnormal cervical 
smear result referred to the colposcopy clinic for a see and treat policy.
Patients and Methods
Population
In the Netherlands, cervical (pre-)cancer screening is performed between 30 and 60 
years of age on a 5-yearly basis. All smears are performed by General Practitioners. In 
case of atypical squamous cells of undetermined significance (ASCUS) or a low-grade 
squamous intraepithelial lesion (LSIL) smear result, high-risk human papillomavirus 
(hrHPV) testing is incorporated with the repeat smear after 6 months. W om en are 
referred for colposcopy by their general practitioner with a high-grade squamous
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intraepithelial lesion (HSIL) smear result or tw o consecutive ASCUS/LSIL smears with a 
positive hrHPV test.
Between December 2007 and April 2010, 197 new referrals to the colposcopy clinic at 
the departm ent of Obstetrics and Gynaecology of the Radboud University Nijmegen 
Medical Centre, the Netherlands, were asked to participate in this study. Twenty-eight 
wom en were excluded for the following reasons: they had previously undergone 
colposcopy (n=18), they were unable to come 15 minutes before the scheduled 
appointm ent (other reasons, n=6), they didn't speak Dutch (n=2), or they declined to 
participate (n=2), see Figure 1. The 169 wom en who participated in the study had 
sufficient knowledge of the Dutch language to read and understand the information 
brochures and to answer the questionnaires, were above the age of 18, and gave 
written informed consent.
Power calculation indicated that in order to have 80% power and to find a decrease of 
6 points on the STAI anxiety scores (maximal score=80, SD 12), with a 5% difference 
between the groups, 64 evaluable subjects were needed in each group. Consequently, 
at least 128 wom en needed to be included to draw statistically validated conclusions. 
To allow for a 20-25% drop-out, the target recruitment figure was 170.
Randomisation
W om en were contacted by a research nurse by phone, some days after making an 
appointm ent for their first colposcopy. After explaining the aim of the study, wom en 
were asked to participate. Those who participated underwent immediate blinded 
pre-contact randomization using sealed envelopes. Wom en randomised foradditional 
information (group A) received targeted information on an individual level based on 
their personal knowledge by phone and by mail. The verbal conversation was 
structured into seven topics (explanation about smear result, pre-cancer instead of 
cancer, colposcopic procedure, possible invasive treatment, HPV, HPV vaccination, 
and fertility) that were subsequently discussed as extensively as individual wom en 
required. In addition to the standard folder of information, they received an 16 page 
docum ent obtained from the Dutch National Society of Obstetrics & Gynecology by 
mail. This set of information describes in detail the aim of the screening program, the 
procedure of taking a cervical smear, the meaning of an abnormal smear result, and 
all possible diagnostic and treatment options that follow an abnormal smear result. 
This docum ent was illustrated to aid understanding. The control group (group B) 
received the standard 2-page colposcopy information leaflet which gives a brief 
description about colposcopy and the possibility of immediate treatment by excisional 
procedures. W hen questions were asked over phone, they were answered without 
more information being offered spontaneously.
On arrival at the colposcopy clinic, wom en were asked to complete the questionnaires.
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Figure 1 flow diagram of subjects through the trial
Women assessed for eligibility 
(n=197)
Excluded (n=28)
♦ Not meeting inclusion criteria (n=20)
• Previous colposcopy (n=18)
• Insufficient Dutch (n=2)
♦ Declined to participate (n=2)
♦ Other reasons (n=6)
Randomised (n=169)
------ 1----------/
/ A llo c a t io n '«
Group A (additional information) Group B (control arm)
(n=84) (n=85)
♦ Received allocated intervention (n=84) ♦ Received allocated intervention (n=85)
■ A n a ly s is /
Group A analysed (n=75) Group B analysed (n=74)
♦ Excluded from analysis (n=9) ♦ Excluded from analysis (n=11)
- Questionnaires were not (completely) - Questionnaires were not (completely)
filled out(n=7) filled out (n=9)
- Not attending their colposcopy - Not attending their colposcopy
appointment (n=2) appointment (n=2)
Psychological measures
State anxiety was measured by means of the Dutch version of the Spielberger State 
and Trait Anxiety Inventory (STAI), a scale that shows satisfactory reliability and 
validity.12 The inventory has 20 items that assess state anxiety; the score for each item 
ranges from 1 to 4, with higher scores indicating greater state anxiety. Total scores 
therefore range from 20 to 80.
Depression was measured by the Hospital Anxiety and Depression scale (HADS) 
developed by Zigm ond and Snaith in 1983.'3 The scale consists of 14 items (7 items for 
both anxiety and depression), all items are scored on a 4-point scale from 0 to 3.
The questionnaires were completed with a short self-administered questionnaire with
24 additional questions about patient demographics, knowledge of cervical cancer, 
knowledge of HPV, knowledge about colposcopy, and satisfaction with the provided 
information by the general practitioner and gynaecology department.
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Statistical analyses
Comparisons were made between wom en who received additional information by 
phone and by mail before their first colposcopy, and wom en who received no 
additional information besides the standard colposcopy leaflet. All statistical analyses 
were performed using the Statistical Package for the Social Sciences program (SPSS 
version 16.0).
Most questions were dichotomous variables. The variables which consisted of a 
scale/range (satisfaction with GP, satisfaction with gynaecologist, smear result, and 
knowledge about HPV) were reduced to clinically relevant dichotomous variables to 
facilitate statistical comparison.
Fisher's Exact, Mann W hitney U, and X- tests were used whenever appropriate to 
compare the tw o groups. The effect of the factors displayed in table 1 and the 
'knowledge' and 'satisfaction info gyn' from table 2 on patient anxiety were assessed 
by the linear regression model to verify which determinants had influence on the 
STAI state anxiety and HADS anxiety scores. Correlations between the factors were 
assessed by Pearson's correlation analysis. P values <0.05 were considered statistically 
significant.
Results
Of the 169 women, 84 were randomised into group A (additional information), and 85 
into group B (control arm). After randomization, 9 wom en were excluded from group 
A and 11 wom en from group B because questionnaires were not filled out for logistical 
reasons or wom en failed to attend their colposcopy appointment, leaving 149 wom en 
for evaluation. Thus, there were 75 wom en in Group A and 74 wom en in Group B, as 
shown in Figure 1. No statistically significant differences were found between the 
groups for any of the patient characteristics (see Table 1).
Table 2 shows the median scores of the STAI and HADS, as well as the knowledge 
about HPV and colposcopy, and the satisfaction with the information given by the 
gynaecology department. Providing additional information for wom en before their 
first colposcopy did not significantly reduce anxiety nor depression. Additionally, the 
satisfaction about the information provided by the gynaecology department did not 
differ significantly between the two groups. However, wom en who received the 
additional information demonstrated significantly more knowledge about HPV and 
colposcopy than those who did not (p=0.004).
Further analyses were performed to identify wom en at high risk of anxiety that may 
be targeted for interventions. Because no difference in anxiety and depression scores 
existed between the two groups, the 149 wom en were considered as a whole for 
further analyses. Table 3 shows the significant correlations of the interacting variables
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Table 1 Patient characteristics
Group A
(additional
information)
Group B 
(control)
Total p-value
Age, median (iq range) * 34.0 (30-40) 34.5 (30-41) 34.0 (30-40) 0.60
Education > college (%)** 47.3 47.3 47.3 1.00
Having a partner (%)** 86.5 82.2 84.4 0.50
Smear > LSIL (%)** 24.2 31.8 28.1 0.43
Came alone to clinic (%)** 31.1 27.0 29.1 0.72
Satisfaction info GP, 
median (iq range)*
9.0 (8.0-9.75) 9.0 (8.0-9.0) 9.0 (8.0-9.0) 0.60
Experienced waiting time, 
median (iq range)*
2.0(1.0-2.0) 2.0 (1.0-2.0) 2.0(1.0-2.0) 0.93
* Mann-Whitnev i./test 
** Fisher's exact
GP, general practitioner; iq, Interquartile
within the whole group. W om en who were highly educated were more likely to come 
alone to the colposcopy clinic, have a low grade cytological smear and be satisfied 
with the information given by the gynaecology department. W omen who came alone 
to the colposcopy clinic were more likely to have a low grade cytological smear. 
Additionally, as discussed before, wom en who received additional information (group 
A) had more knowledge about HPV and colposcopy.
We performed a univariate analysis for the STAI and HADS anxiety scores of the variables 
displayed in table 1 and the ’knowledge' and 'satisfaction info gyn' from Table 2. 
Interactive correlations were calculated for all variables. There was no Pearson 
correlation above 0.40. Therefore, all factors from the univariate analyses were entered 
the linear regression analysis. The results are displayed in Table 4a and 4b. Because a 
few questions were left blankon some of the completed questionnaires [coming alone 
to the clinic (n=1), satisfaction with the GP (n=24), the referral smear result (n=21 )] the 
groups presented do not add up to 149. W om en who came alone to the colposcopy 
clinic had significantly lower STAI state anxiety scores than wom en who brought 
someone to accompany them (p<0.001). Women also had significantly lower STAI state 
anxiety scores when they were satisfied with the information given by their general 
practitioner. Twenty percent of the difference in STAI state anxiety scores was explained 
by these two variables (Rsq 0.20). W ith respect to the HADS anxiety scores, the decision
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Table 2 Possible dependants of intervention
Group A
median (iq range)
Group B
median (iq range)
Total
median (iq range)
p-value
STAI state* 48.0 (42.0-56.0) 50.0 (40.0-59.0) 50.0(41.0-57.0) 0.92
STAI trait* 33.0(27.0-41.0) 33.0(27.0-41.3) 33.0(27.0-41.0) 0.96
HADS anxiety* 5.0 (3.0-9.0) 6.0(4.0-10.0) 6.0 (3.0-9.0) 0.26
HADS depression* 1.0 (0.0-5.0) 1.0 (0.0-4.0) 1.0 (0.0-4.0) 0.73
Satisfaction info gyn* 16.0(15.0-19.0) 15.0(14.0-18.0) 15.0(15.0-18.75) 0.06
Knowledge* 4.0 (3.0-4.0) 3.0(1.0-4.0) 4.0(1.5-4.0) 0.004
* Mann Whitney U test 
Iq, interquartile
Table 3 Significant Pearson correlation between variables
Alone to 
clinic
Smear 
< LSIL
Education 
> college
Satisfied 
info gyn
Group
A
Knowledge
Alone to clinic X 0.18* 0.17*
Smear < LSIL 0.18* X 0.26**
Education > college 0.17* 0.26** X 0.20*
Satisfied info gyn 0.20* X
Group A X 0.28**
Knowledge 0.28** X
M <  0.05 
*M <  001
to come alone to the colposcopy clinic was associated with significantly lower anxiety 
scores (p=0.04), as was having low grade cytology on the referral smear (p=0.04); 
satisfaction with the general practitioner did not affect the HADS anxiety score.
The STAI state and trait scores correlate highly (Spearman's r 0.43, p<0.01), as well as 
the HADS anxiety and depression scores (Spearman's r 0.64, p<0.01). W hen the STAI 
trait score is considered to be the baseline score, only educational level showed 
significant differences in baseline (p=0.01). Higher educated wom en had lower
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Table 4a Linear regression STAI state anxiety
STAI state p-value 
(median)
Alone to clinic yes (n=43) 40.5 <0.001
no (n= 105) 52.0
Satisfied with info GP yes (n=83) 48.5 0.04
no (n=43) 52.0
P6q=0j0
GP, general practitioner
Table 4b Linear regression HADS anxiety
STAI state 
(median)
p-value
Alone to clinic yes (n=43) 5.0 0.04
no (n= 105) 7.0
Smear result < LSIL (n=92) 5.0 0.04
>LSIL (n=36) 8.0
Póq=0.0S
median baseline STAI trait scores than lower educated women, respectively 31.0 
versus 35.8. W e may hypothesize that the intervention of additional information 
(group A) has more influence on a group with low baseline anxiety scores. The HADS 
anxiety scores, however, did not significantly differ between group A and B of the 
highly educated wom en (p=0.13).
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Discussion
In this randomised controlled study we investigated the effect of individually targeted 
information by mail and by phone on anxiety in wom en who were for the first time 
referred to the colposcopy clinic. We found no statistical difference in STAI state/trait 
anxiety and HADS anxiety/depression scores between wom en who did or did not 
receive individually targeted information before colposcopy. Knowledge about HPV 
and colposcopy did increase significantly in the wom en who received additional 
information about the diagnosis and procedure (p=0.004). However, increasing 
knowledge did not reduce women's anxiety before colposcopy.
Consistent with other studies, we found high overall levels of STAI state anxiety in 
wom en being referred for colposcopy with abnormal cervical smears, with a median 
STAI state anxiety score of 50.0. This is similar to the level of anxiety in wom en just 
before colposcopy reported in previous studies.5111416 These levels are surprisingly 
high, especially if we compare these levels with anxiety levels of 42.9 in preoperative 
wom en.17 For Dutch wom en undergoing IVF treatment, pre-treatment anxiety levels 
of 37.3 (Sd 11.7) are reported.18 This should be a concern to anyone involved in 
colposcopy. Trait anxiety scores fell within the range of normal Dutch wom en12, 
indicating that the high levels of anxiety experienced by these wom en are not due to 
personality traits, but probably evoked by this specific situation.
Information supply before primary colposcopy in the form of leaflets or handouts has 
not been shown to significantly decrease women's STAI state anxiety.1416 In our study, 
anxiety was not influenced by the additional information given before colposcopy 
either. Other factors, like the participant's satisfaction with their general practitioner, 
or the grade of the referral cervical smear had more influence on STAI state anxiety 
and HADS anxiety, irrespective of the information given. Both factors were associated 
with significantly lower anxiety scores (both p=0.04). It is not unexpected that wom en 
with more severe cytological smears experience higher anxiety levels. The way these 
screening results are communicated with the patients, however, may vary. The general 
practitioner, as a confidant, may play an important role in this manner. The satisfaction 
with the information provided is previously reported as a predictor for anxiety.811 
Furthermore, wom en who decided to come to the colposcopy clinic w ithout social 
support, had significantly lower anxiety scores. No correlation was seen between 
having a partner and bringing someone to the colposcopy clinic. The decision to 
bring no social support is therefore not dependant of having, or not having a partner. 
Probably, it is the other way around, wom en who experience less anxiety before 
colposcopy, are less inclined to bring social support to the colposcopy clinic. 
Although additional information did not decrease anxiety, it did significantly increase 
knowledge about HPV and colposcopy. This effect has also been reported in other 
studies.1416 Increasing knowledge about the diagnosis and the procedure, and pre­
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colposcopy sessions have been associated with a better attendance rate.1419 
Other interventions designed to reduce anxiety levels before and during colposcopic 
examination have been reported.20 These interventions include pre-colposcopic 
counselling, information videos, information using graphs, listening to music during 
colposcopy, and viewing the video colposcopy during the examination. Showing 
information videos prior to colposcopy in combination with an information leaflet 
was associated with a greater reduction in anxiety than providing an information 
leaflet alone (pcO.OOOOl).5 Walsh et al, randomised 81 wom en into a 'video colposcopy' 
and a control group. Viewing video colposcopy during the procedure was associated 
with a significant decrease in anxiety levels (p<0.0002).21 Furthermore, anxiety 
appeared to be reduced by playing music during colposcopy. A randomised trial in 
which they compared wom en who listened to music during the procedure and 
wom en who did not, showed that listening to music during colposcopic examination 
was associated with a mean anxiety reduction o f -4.80 (95% Cl -7.86 to -1.74; p=0.002).22 
W e showed that additional targeted information on an individual level did not 
significantly reduce anxiety levels before colposcopic examination. Relatively few 
studies have found that anxiety can be reduced by simple interventions before or 
during colposcopy. Interventions that increase knowledge, dispel myths and put the 
abnormal smear into context may provide some comfort but anxiety is probably a 
normal reaction to an abnormal smear result. It is unclear whether it is possible or 
even desirable to abolish anxiety completely, as attendance may be driven, at least in 
part, by fear of not attending. Interventions aimed at reducing excessive anxiety may 
be more realistic and qualitative research based on focus group discussions may be 
helpful in this regard.
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CHAPTER 5
Abstract
Introduction. Vulvar squamous cell carcinoma (SCC) originates following two 
pathways, related to differentiated (d) vulvar intraepithelial neoplasia (VIN) or to 
human papillomavirus (HPV)-related usual (u) VIN. Multicentric HPV infections (cervix, 
vagina and vulva) are common. W e hypothesise that patients with a uVIN related 
vulvar SCC more often have cervical high-grade squamous intraepithelial lesions 
(HSIL) compared with wom en with dVIN related vulvar SCC.
Methods. All vulvar SCCs (201) were classified to be dVIN (n=164) or uVIN related 
(n=37). Data with regard to the smear history and cervical histology were retrieved 
from PALGA, the nationwide Netherlands database of histo- and cytopathology. For 
HSIL cervical smears of which histology was taken, HPV DNA analysis on both the 
vulvar and cervical specimens was performed.
Results. At least one smear was available in 145 (72%) of the 201 patients. Patients 
with a uVIN related vulvar SCC more often had an HSIL compared with patients with a 
dVIN related SCC (35% vs 2%, pcO.OOl). A total of 10 of the 13 HSILs were histologically 
assessed and identical HPV types were found in the vulva and cervix.
Conclusion. These data emphasise the necessity to differentiate between dVIN- and 
uVIN-related vulvar tumours and to examine the entire lower female ano-genital tract 
once an uVIN-related lesion is found.
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Introduction
Vulvar squamous cell carcinoma (SCC) accounts for 3-5% of all gynaecological 
malignancies and originates following two separate pathways. One type of vulvar 
SCC, accounting for -80%, occurs mainly in older patients and is mostly of the 
keratinising type, associated with lichen sclerosus (LS) and/or differentiated vulvar in- 
traepithelial neoplasia (dVIN) as premalignant lesions. The other type, accounting for 
-20%, is human papillomavirus (HPV) related, occurs in younger patients, and has 
usual VIN (uVIN) as premalignancy.1 Recently, we found that uVIN associated vulvar 
SCC patients had a significantly better disease free survival than dVIN associated 
vulvar SCC patients.2 The majority of uVIN related vulvar SCCs are caused by HPVs 16, 
18 and 33.3-7 The developm ent of uVIN and vulvar SCC mirrors that of cervical intrae- 
pithelial neoplasia (CIN) and cervical SCC, the latter caused by hrHPV in nearly 100% of 
the cases.8' 9 A subdivision on the basis of hrHPV DNA presence between the two 
types of vulvar SCC does not separate the two different pathways accurately. High-risk 
HPV presence does not per se indicate a causal role in the carcinogenesis and may 
represent a non-significant or transient infection. A better method of subdividing the 
tw o types of vulvar SCC is on the basis of the histology of the adjacent VIN lesion.1012 
Multicentric HPV infections affecting vulva, cervix, vagina and anus simultaneously 
have been described in several studies8,14“1,8, making a thorough examination of the 
entire lower female ano-genital tract obligatory. A decreased immune response to 
hrHPV has been suggested to be the cause of these multicentric hrHPV infections17, 
although it is also possible that HPV affects cervix and vulva consecutively.
In this study we investigate whether patients with uVIN-related vulvar SCCs more 
often have abnormal cervical smears and/or histologically confirmed cervical (pre) 
malignancies compared with wom en with dVIN/LS related vulvar SCC. Moreover, we 
investigate which hrHPV types play a role in either uVIN related vulvar SCCs and 
cervical (pre)malignancies.
Patients & Methods
Between 1988 and 2007,209 consecutive patients were treated fortheir primary invasive 
or recurrent SCC of the vulva at the Radboud University Nijmegen Medical Centre, The 
Netherlands. Data were stored in a database. All histopathological slides were revised to 
classify the adjacent lesion as uVIN, LS and/or dVIN, to categorise the vulvar cancers into 
uVIN or dVIN related.1922 In eight cases, the subdivision was impossible because the 
diagnosis of the type of VIN lesion was uncertain because of massive intraepithelial 
inflammation, epithelial destruction due to massive ulceration or because the required 
tissue was not available. The remaining 201 patients constituted the study population.
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Cervical smears
Data with regard to the smear history and cervical histology were retrieved from 
PALGA, the nationwide Netherlands database of histo- and cytopathology. This 
database has had national coverage from 1991 onwards, showing all surgical 
specimens and cervical smears ever taken from each patient, both by the general 
practitioner and medical specialists.24 The cervical histology and smear history were 
available for all 201 patients.
Cervical smears were subdivided into smears taken more than one year before the 
diagnosis of vulvar SCC; smears taken within one year before the diagnosis of vulvar 
SCC; and smears taken after primary treatment for vulvar SCC.
In case multiple smears were taken during the study period, the most severe lesion 
was used for the analysis. Histology was preferred above cytology.
Histology of adjacent VIN lesion
A subdivision on the basis of the histology of the adjacent VIN lesion (we adopted the 
new ISSVD classification25) was considered the most appropriate method to subdivide 
the vulvar SCCs into a pathway.11 Every original surgical specimen was revised for 
the presence of LS and/or VIN lesions, based on the current histopathological 
characteristics.26 If a patient had a high-grade squamous intraepithelial lesion (HSIL) 
resulting in a histological diagnosis, these specimens were retrieved in order to 
perform HPV DNA analysis on both the vulvar and cervical specimens. The presence 
of HPV was determined and genotyping was performed w ithout the knowledge of 
patients' correlating tissues.
SPF10-INNO LiPA HPV detection and genotyping
DNA was isolated from formalin-fixed paraffin-embedded tissue sections (6|am) with 
the EZ1 robot (with the DNA tissue kit of Qiagen Inc, Valencia, CA, USA) according to 
the standard procedures and used for PCR analysis. A negative water control was 
included with each batch of 10 samples. Broad-spectrum HPV DNA amplification was 
performed using a short PCR fragment assay (HPV SPF10 Line Blot 25, Labo Bio-medical 
products BV Rijswijk, The Netherlands). This assay amplifies a 65-bp fragment of the LI 
open reading frame, and allows detection of a broad range of high-risk (hr), low-risk 
(Ir) and possible hrHPV genotypes.27' 28 Twenty-eight oligonucleotide probes that 
recognize 25 different types were tailed with poly(dT) and immobilised as parallel 
lines to membrane strips (Labo Bio-medical products B.V. Rijswijk, the Netherlands). 
The HPV genotypes detectable are hrHPV 16,18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, and 
68/73 and two probable hrHPV types (53 and 66), and IrHPV genotypes 6, 11, and so 
on. The HPV genotyping assay was performed as described earlier.29 The line probe 
assay (LiPA) strips were visually inspected, and interpreted using the provided 
reference guide. As a quality control for the presence of DNA and absence of PCR
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inhibitors in the isolated material a (3-globin PCR was performed, as described by 
Snijders et al.™ For the real-time PCR method, 5 pL of DNA was used.
Statistical methods
The Kolmogorov-Smirnov test was used to evaluate whether the variables age, year of 
diagnosis, and first-line treatment of the tw o groups had a normal distribution. As the 
variables were not all normally distributed, all analyses were performed using non- 
parametrical tests. For analytical purposes, the histology and pap smears were 
subdivided into the Bethesda nomenclature, low-grade squamous intraepithelial 
lesions (LSILs) or less, and at least an HSIL. The Fisher's exact test was used to compare 
hrHPV presence in uVIN and dVIN lesions adjacent to vulvar SCCs and to compare the 
different groups of vulvar SCC patients with respect to cervical abnormalities. P values 
presented are two-tailed and the results were statistically significant at p <0.05.
Results
The data of a total number of 201 patients were analysed. The median age of the 
patients at diagnosis was 71 years (range 30-92). The median age at diagnosis of the 
dVIN/LS-related pathway group (72 years, range 31-92) and the uVIN-related pathway 
group (54 years, range 30-88) differed significantly (pcO.OOl).
Histology of the adjacent VIN lesion and HPV
Histopathological review of the VIN lesion directly adjacent to the tumour led to a 
total number of 37 (18%) tumours that were considered to follow the uVIN related 
pathway, and 164 (82%) that were considered to follow the dVIN/LS related pathway. 
O f the 164 dVIN/LS related tumours, 54 (33%) tissues showed solitary dVIN, 22 (13%) 
tissues showed solitary LS and 88 (54%) tissues showed dVIN in combination with LS, 
as surrounding lesions. Of 168 tumours (32 uVIN and 136 dVIN/LS), both histology of 
the adjacent VIN lesion and HPV presence and typing could be performed. O f the 
uVIN-related tumours, 27 of the 32 (84,4%) were found hrHPV positive and 13 out of 
136 (9,6%) of the dVIN/LS-related tumours were found hrHPV positive (Table 1). For the 
uVIN-related pathway, high-risk HPV types predominated, in particular types 16 (62%) 
and 33 (17%).The other 21 %  were caused by types 18,52and 58.0 fthe 13 hrHPV-positive 
tumours in the dVIN related pathway, six tumours were found HPV 16 positive (46%) 
and the other seven were found HPV 18, 33, 52, or 53 positive.
Smear histories
From 28% of the patients, no cervical smears or cervical biopsies had ever been taken. 
These patients had a median follow-up after their vulvar SCC of eight years (range
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Table 1 Distribution of high-risk human papillomavirus (hrHPV) in relation to
the pathological pathway in 168 tissues of which both HPV DNA analysis 
and pathologic pathway was available, p < 0.001
HRHPV+ hrHPV- Total
uVIN 27 5 32
dVIN/LS 13 123 136
Total 40 128 168
uVIN, usual vulvar Intraepithelial neoplasia; dVIN, differentiated vulvar intraepithelial neoplasia; 
LS, Lichen Sclerosus
1-20), w ithout any clinical indication of cervical disease; 87% of these wom en were 
older than 55 years of age from the start of the national screening program for cervical 
cancer in 1988, as a result of which they exceeded the age limit to be invited. Of the 
145 patients from whom  at least one smear was available, the most severe lesion was 
taken: of these patients, 9.0% (n=13) had a smear indicating an HSIL. Patients with uVIN 
related tumours had significantly more cervical smears indicating an HSIL, compared 
with patients with LS/dVIN related tumours, 11 of 31 (35%) and 2 of 114 (2%) (p<0.001) 
respectively (Table 2).
Table 2 Total cervical specimens/smears of patients with vulvar squamous cell 
carcinoma, subdivided between two different pathways, related to 
lichen sclerosus (LS) / differentiated vulvar intraepithelial neoplasia (dVIN), 
or usual VIN (uVIN), p<0.001
LS, dVIN-related pathway uVIN-related pathway
< LSIL 112(98%) 20(65%)
> HSIL 2 (2%) 11 (35%)
LSIL, low grade squamous intraepithelial lesion; HSIL, high grade squamous intraepithelial lesion
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HSIL on cytology, histologically assessed
Histological specimens were examined after an HSIL smear in 10 of the 13 patients: in 
tw o cases there was a CIN I lesion, seven were CIN III lesions and one seemed to be an 
invasive cervical SCC. Chronologically, in five cases the CIN lesion was diagnosed 
before the vulvar SCC with an interval in time from 5 to 13 years (case 2;3;7;8; and 10); 
in four cases the CIN lesion was diagnosed simultaneously with the vulvar SCC (case 
1;4;6; and 9); in one case the CIN lesion was diagnosed 6 years after the vulvar SCC 
(case 5).
Three patients with HSIL on cytology had, remarkably, no histological follow up. One 
patient died on account of a vulvar recurrence soon after the HSIL was diagnosed. 
One had a cytological follow-up with normalisation of the smears in five years without 
interference of biopsies or excisions. The other particular patient was diagnosed with 
a vulvar SCC in 2004 and simultaneously had a HSIL on cervical cyto logy without 
further cervical follow up. A total of nine of the ten histologically confirmed tumours 
showed uVIN in the surrounding tissue and were HPV DNA positive. The one that 
showed dVIN in the surrounding tissue was HPV DNA negative. A cervical lesion of 
one patient showed negative (3-globin after DNA extraction. In all tissues of the other 
eight patients, the same HPV types were found in both the vulvar and cervical 
specimens (Table 3).
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Table 3 Ten cases of vulvar SCCs and cytologically a high grade squamous 
intraepithelial lesion of the cervix with histological correlating lesion 
and HPV types
Case Adjacent lesion Year Age Type of tumour HPV
1 uVIN 2007 65 Vulvar SCC 16
2007 65 Cervical SCC 16
2 uVIN 1990 34 VIN III 33
1990 34 Cervical carcinoma in situ 33
uVIN 2003 47 Vulvar SCC 33
3 1990 38 CIN III 16
uVIN 2003 51 Vulvar SCC 16
4 uVIN 1998 37 Vulvar SCC 16
1998 37 CIN III 16
uVIN 2006 45 Vulvar SCC 16
5 uVIN 1999 45 Vulvar SCC 16,52
2005 51 CIN III 52
6 uVIN 2004 37 Vulvar SCC 16,18,54
2004 37 CIN III 16
2007 40 CIN III 16
7 1986 37 CIN III 58
uVIN 1992 43 Vulvar SCC 58
8 1997 48 CIN 1 16
9 uVIN
uVIN
2002
2004
2004
53
58
58
Vulvar SCC
Vulvar SCC 
CIN 1
16,58
16
B-globin neg
10 1994 49 CIN III 31
LS+dVIN 2005 60 Vulvar SCC negative
SCCs, squamous cell carcinomas; HPV, human papillomavirus; uVIN, usual vulvar Intraepithelial neoplasia; 
dVIN, differentiated vulvar Intraepithelial neoplasia; LS, Lichen Sclerosus; CIN, cervical intraepithelial 
neoplasia
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Discussion
Our study on a large group of patients with vulvar SCCs (201 cases), with regard to 
cervical (pre)malignancies, showed that 9%  of all patients with available cytology of 
the cervix had a smear suggestive for a HSIL. Divided between the two pathways, 35% 
of the patients with uVIN-related vulvar SCCs had a smear suggestive for a HSIL, 
compared with only 2%  of patients whose vulvar SCC was dVIN related (pcO.OOl). For 
uVIN related SCCs, this is a more than tenfold incidence compared to the overall 
incidence of a HSIL in The Netherlands.31 In 19% (n= 7) of the total 37 patients with a 
uVIN-related vulvar SCC, a histologically proven cervical HSIL or SCC was found during 
a follow-up of 20 years. Moreover, all of these uVIN-related vulvar SCCs and cervical 
lesions in the same patient showed the identical hrHPV type. These identical hrHPV 
types were seen in vulvar SCCs and cervical lesions even after an interval of more than 
ten years. This may be one long-standing infection or a new infection with the exact 
same type of virus. Particularly as less common types were found as well, a 
long-standing infection is most likely. Furthermore, if a patient's immune system is 
not able to clear a hrHPV infection, that patient is thought to be more prone to 
develop multicentric (pre)malignancies. In most cases, the cervical lesion preceded 
the vulvar SCC, although vulvar SCCs preceding cervical lesions were seen as well. 
The difficulty is whether the date of diagnosis accurately reflects the origin of the 
lesions. It may well be possible that these lesions had initially been asymptomatic and 
present for a longer period before diagnosis. Our data suggest that the identical 
long-standing hrHPV infection is causing these multicentric (pre)malignancies. This 
emphasises the concept that a patient with a hrHPV-related ano-genital (pre) 
m alignancy is at higher risk to develop another hrHPV-related (pre)malignancy. We 
previously reported that 41% of uVIN patients had a past, simultaneous or future 
HPV-induced cervical, vaginal or anal lesion.32 Unfortunately, in this cohort of vulvar 
SCC patients, we were not able to retrieve data about other multicentric sites of the 
lower female ano-genital tract prone to hrHPV infection.
This higher risk to develop other hrHPV-related (pre)malignancies obliges us to 
differentiate between dVIN and uVIN lesions followed by a precise examination of the 
entire lower female ano-genital tract in case of a vulvar carcinoma, especially in case 
of a tumour from the uVIN-related pathway.
In general, several studies showed that patients with uVIN-related vulvar SCC are 
younger than dVIN/LS related vulvar SCC patients.2 4'2224 In our study, we confirm this 
observation with a significant difference in age distribution between the tw o different 
groups, 72 yrsfor the hrHPV-unrelated and 54yrsfor the hrHPV related group (p<0.001). 
If we compare the median age for cervical SCC, which is caused by hrHPV in nearly 
100% of the cases, with the median age for uVIN/hrHPV-related vulvar SCC, we find a 
comparable age, 51 yrs and 54 yrs respectively.25 This may suggest that a hrHPV
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infection brings about an earlier age of onset of uVIN-related vulvar carcinogenesis 
compared with the dVIN related vulvar carcinogenesis. In this study, cervical (pre) 
malignancies with compatible hrHPV types were diagnosed as well before, 
simultaneous as after a uVIN related vulvar SCC.
We found a hrHPV prevalence of 23.4% for vulvar SCC in general. The percentage of 
hrHPV DNA-positive vulvar SCC (23.4%) is slightly higher than the percentage of 
tumours with adjacent uVIN (18.4%). These findings confirm that not all hrHPV 
infections finally lead to vulvar SCC. As hrHPV often resolves spontaneously, most 
likely these five percent additional infections were transient infections, yet to be 
cleared.
O f the 201 patients, in 56 cases (28%) no cervical smear information was available: this 
may be due to limitation in coverage of the PALGA database (national coverage from 
1991 onwards) or because of the fact that these wom en never had a cervical smear 
taken. Worth mentioning is that 87% of these wom en exceeded the age limit to be 
invited for the national screening program for cervical cancer. Still, at diagnosis, in 105 
of the 201 (52%) cases no cervical smear was taken around the diagnosis of the vulvar 
SCC. Approximately one-fifth of the vulvar SCCs is uVIN-related, and simultaneous 
cervical and vulvar infections have previously been described.1416' 18 Therefore, a 
cervical smear should always be taken during the diagnostic process of patients with 
a uVIN-related vulvar SCC. During the studied period (1988-2007), the role of hrHPV 
became more evident. In this study, for all patients diagnosed after 2002, a cervical 
smear was taken. This suggests that the cervical smear is now more em bedded in the 
diagnostic routine of vulvar SCC. Our results show that it is important not to overlook 
or underestimate the possibility of a multicentric HPV infection, causing both cervical 
and vulvar (pre) malignancies. Although there is no evidence, probably because of 
the low number of patients that developed a HSIL lesion after vulvar SCC, we would 
suggest: all vulvar SCC patients have a cervical smear during the diagnostic process of 
their vulvar SCC; for uVIN-associated vulvar SCC patients a two yearly cervical smear 
should be performed during follow up.
In conclusion, patients with a uVIN-related vulvar SCC have an increased incidence of 
cervical (pre) malignancies with identical hrHPV types in both cervical and vulvar (pre) 
malignancies. This points to the multicentric developm ent of (pre)malignancies and 
emphasises the necessity to differentiate between dVIN- and uVIN-related vulvar 
tumours. The examination of the entire lower female ano-genital tract in case of a 
hrHPV-related vulvar lesion should therefore be obligatory.
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CHAPTER 6
Abstract
Objective. This study assesses human papillomavirus (HPV) detection and genotyping 
in self-sampled genital smears applied to an indicating FTA elute cartridge (FTA 
cartridge).
Methods. The study group consisted of 96 women, divided in two sample sets. All 
samples were analysed by the HPV SPF10-Line Blot 25. Set 1 consisted of 45 wom en 
attending the gynaecologist; all obtained a self-sampled cervicovaginal smear, which 
was applied to an FTA cartridge. HPV results were compared to a cervical smear 
(liquid-based) taken by a trained physician. Set 2 consisted of 51 wom en who obtained 
a self-sampled cervicovaginal smear at home, which was applied to an FTA cartridge 
and to a liquid-based medium. DNA was obtained from the FTA cartridges by simple 
elution as well as extraction.
Results. O f all self-obtained samples of set 1, 62.2% tested HPV-positive. The overall 
agreem ent between self- and physician-obtained samples was 93.3%, in favour of the 
self-obtained samples. In sample set 2, 25.5% tested HPV positive. The overall 
agreem ent for high-risk HPV (hrHPV) presence between the FTA cartridge and 
liquid-based medium and between DNA elution and extraction was 100%. 
Conclusions. This study shows that HPV detection and genotyping in self-obtained 
cervicovaginal samples applied to an FTA cartridge is highly reliable. It shows a high 
level of overall agreem ent with HPV detection and genotyping in physician-obtained 
cervical smears and liquid-based self-samples. DNA can be obtained by simple elution 
and is therefore easy, cheap, and fast. Furthermore, the FTA cartridge is a convenient 
medium for collection and safe transport at ambient temperatures. Therefore, this 
method may contribute to a new way of cervical cancer screening.
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Introduction
Infection with human papillomavirus (HPV) is a necessary event in the multistep 
process of cervical carcinogenesis.12 As a result, the clinical value of HPV testing has 
been well-established.3 8 In the United States, the Food and Drug Administration 
(FDA) has authorized high-risk HPV (HRHPV) assessment for primary screening in 
wom en aged 30 and older. This is in addition to regular cytological screening as well 
as for the triage of smears with atypical cells of undetermined significance. In the 
Netherlands, additional HRHPV testing has been approved and recommended in all 
follow-up smears after the detection of a first-time borderline or mild dysplasia smear. 
The beneficial effect of HPV testing will most likely increase in case HRHPV assessment 
replaces cytology as primary screening tool.3'4'6 ,8
Regarding (HR-)HPV testing, material from vaginal lavages or self-sampling brushes 
has proven to be highly representative for the cervical (HR-)HPV status.914 In addition, 
cervicovaginal self-obtained samples have repetitively been proven to be as reliable 
as physician-taken samples.15' 16 Subsequently, several studies have shown that 
self-sampling for HPV testing was highly acceptable to women, although some 
wom en were concerned about performing the test properly.11' 17 HRHPV testing on 
self-sampled materials might be a promising opportunity to increase the efficacy of 
population-based screening programs worldwide.9 lft u  18 Cervicovaginal self-sampling 
may be an easy, accessible, user-friendly, and time-saving alternative for the physician- 
based collection of cervicovaginal material.11'17
In the Dutch cervical screening program, approximately 70% of the wom en invited 
actually take part. Tragically, half of the cervical carcinomas are diagnosed in the 
remaining group of non-responders.12'19 20 Cervical cancer incidence would decrease 
significantly if these non-responders could be reached.5 6 Several studies have shown 
that non-responders do actually take part in self-sampling studies.912 21 Self-sampling 
is a less-costly and a less-invasive collection method.16 Self-sampled material could be 
more easily obtained in populations that are difficult to reach and in settings with 
limited resources, facilitating the introduction of organized HPV-based cervical 
screening programs in developing countries as well.
However, the vast majority of studies assessing self-sampling have used liquid-based 
storage and transport media.9 12 u  21 Since these solutions can be inflammable, 
hazardous, and potentially infectious, careful handling is required and regular mailing 
may even not be allowed. This severely hampers the introduction of cervicovaginal 
self-sampling methods. Dried fluid spots or solid carriers have already been used for 
decades in the postnatal screening of certain congenital disorders and diseases. Solid 
carriers have also been successfully used in studies detecting and genetically 
characterizing measles virus strains, as well as in studies assessing viral load and 
genotypic resistance for human imm unodeficiency virus (HIV).2224 As dried material
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on a solid carrier is neither hazardous nor inflammable, applying genital self-samples 
on these solid carriers (like FTA cartridges) can solve storage and transportation 
problems.
In this study, we have assessed the use of self-sampled cervicovaginal smears applied 
to a new FTA cartridge, i.e., the Whatman indicating FTA elute cartridge (Figure 1 and 2) 
which allows easy storage and transport, as the virus is denaturized upon application. 
Additionally, the cartridge overcomes the uncertainty of wom en about performing 
the procedure properly, as it has an indicating dye which changes from purple to 
white when a (genital) sample is applied. Furthermore, we assessed the novel method 
of direct HPV DNA elution w ithout requiring further purification.
Figure 1A Whatman indicating Figure IB  Whatman indicating
FTA elute cartridge FTA elute cartridge upon
application
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Figure 3 Study design
Total number of participants 
n=96
Sample setl 
Outpatient clinic, 23-51 years 
n=45
Sample set 2 
HPV study group, 18-29 years 
n=51
Ce rv ico-vagi nal Physician collected Cervico-vaginal
self-sample cervical smear self-sample
Rovers® Viba-Brush Rovers® Cervex-Brush® Rovers® Viba-Brush
Applied to Applied to liquid Applied to Top applied to liquid
FTA cartridge based medium FTA cartridge based medium
Material and Methods
The study group consisted of 96 women, divided in two sample sets (Figure 3). 
Sample set 1
Between Septem ber and October 2008,45 wom en were recruited at the Department 
of Obstetrics and Gynaecology of the Radboud University Nijmegen Medical Centre, 
the Netherlands. These participants visited the gynaecologist for follow up after 
diethylstilbestrol exposition in utero, treatment of cervical dysplasia, orfo llow  up after 
borderline or mild dysplasia smears. The median age was 38 years (standard deviation,
6.85 years; range, 23 to 51 years).
All women were asked to self-collect a cervicovaginal sample after having received 
instructions on how to perform the self-sample (verbally, written, and in cartoon). In 
brief, participants were instructed to wash their hands before opening the brush cover 
(RoversViba-Brush, Rovers Medical Devices BV, Oss, The Netherlands), to hold the brush
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by the end of the handle, to insert the brush approximately 7 cm into the vagina (similar 
to inserting a tampon), and to gently turn the brush five times. Subsequently, the brush 
was applied to the FTA cartridge (Whatman indicating FTA elute cartridge; catalogue 
number WB 659223; GE Healthcare, United Kingdom) (Figure 1 and 2). The FTA cartridge 
was air dried. After self-sampling, a vaginal speculum was inserted and a physician 
obtained a regular cervical smear using a Rovers Cervex-brush (Rovers Medical Devices 
BV, Oss, The Netherlands) that was rinsed in a ThinPrep vial (Cytyc corp. Boxborough 
MA). Regular liquid-based cytological (LBC) examination was performed, and 0.5ml_ 
LBC homogenized medium was used for HPV assessment.
In order to assess the samples anonymously, all self-obtained samples and cervical LBC 
samples were provided with an unique patient code before they were sent to the 
laboratory.
Sample set 2
Sample set 2 consisted of 51 healthy participants who were randomly recruited from 
a prospective self-sampling study on HPV prevalence, incidence and clearance among 
2065 unscreened wom en between 18 and 29 years of age.25 All wom en were asked to 
self-collect a cervicovaginal sample in the privacy of their own home. Wom en received 
an explanatory letter, an informed consent form, and a self-sample kit by mail. The 
self-sample kit was provided with an anonymous code to ensure privacy. The 
self-sample kit contained a collection device (a small brush packaged in an individual 
sterile cover, Rovers Viba-Brush, Rovers Medical Devices BV, Oss, The Netherlands), an 
FTA cartridge (Whatm an indicating FTA elute cartridge; catalogue number W B 659223; 
GE Healthcare, UK) (Figure 1 and 2), a collection tube containing medium (Su rePath'11, 
Tripath Imaging, Inc., Burlington NC), instructions how to perform the cervicovaginal 
self-sample (written and in cartoon), and a return package consisting of a leak proof 
seal bag, absorption sheet, and a reclosable plastic return envelope (Easyslider; 
Transposafe Systems Holland BV, Sassenheim, The Netherlands). Except for the fact 
that they used an additional liquid-based medium, the instructions of how to perform 
the self-sample were similar to the instructions described above. In brief, participants 
were instructed to first apply the self-sample on the FTA cartridge and subsequently 
place the top of the brush in the collection tube. The collection tube was closed and 
enclosed in the seal bag. Finally, the collection tube was placed in the return envelope 
together with the dried FTA cartridge and sent to the Department of Obstetrics and 
Gynaecology for further processing and HPV assessment at the Department of Medical 
Microbiology. The samples were stored at room temperature. In the original study of 
the 2065 women, a control for sample sufficiency, i.e. detection of human (3-globin 
was performed and showed less than 1% false negative samples.25 
The self-sampling material on the FTA cartridge was compared to the self-sampling 
material stored in the liquid-based medium (Figure 3).
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Specimen preparation LBC
For isolation of DNA from cervical scrapes in liquid-based cytology medium, the 
MagNAPure LC isolation station (Roche Diagnostics GmbH, Roche Applied Science, 
Mannheim, Germany) was used; 500|jLof material was isolated using the MagNA Pure 
LC total nucleic acid isolation kit (Roche Diagnostics GmbH, Roche Molecular 
Biochemicals, Mannheim Germany), as described by the manufacturer. With each set 
of 28 cervical scrape samples four negative controls were included. Nucleic acid was 
resuspended in a final volume of 50|uL; 10|jL was used for PCR analysis.26
Specimen preparation of the Indicating FTA elute cartridge
The indicating FTA elute matrix contains an indicating dye that changes from purple 
to white upon application of a colourless sample such as cervicovaginal swab. The 
FTA cartridges were punched using a sterilized perforator specifically designed for 
the FTA cartridges (3-mm Harris Uni-Core device; Whatman). The sample amount 
varied between samples, and to optimize the number of punches to cover this 
variation, pilots were performed using a different number of punches. For this study, 
only three punches were considered to compare DNA elution and extraction, as well 
as individual genotypes.
The FTA Elute matrix is chemically treated with proprietary reagents that lyses cells 
upon contact, causing the release of nucleic acids. DNA was recovered from the FTA 
elute matrix through a simplified elution process using heat and water. Inhibitory 
components, such as haemoglobin, are retained on the FTA elute matrix.
Elution
The three punches were transferred into a 1.5-mL microfuge tube and 1500|aL of 
sterile water was added to the punches and immediately pulse vortexed three times, 
for a total of 5 seconds. The water was removed with a sterile fine tip pipette. Fifty 
microliters of sterile water was added to the punches, and the tube was transferred to 
a heating block at 95°C for 30 minutes. At the end of the incubation period, the sample 
was removed from the heating block and pulse vortexed approximately 60 times. It 
was additionally centrifuged for 30s and the eluted DNA was placed into a new micro­
centrifuge tube with a pipette. The eluted DNA was stored at -80°C.
Finally, 10|jL of the eluate was used for PCR analysis.
Isolation
For additional comparison, DNA was extracted from three other punches using the 
Qiagen DNeasy Tissue Kit (Qiagen Inc, Valencia, CA), as described by the manufacturer. 
Subsequently, HPV DNA assessment was performed identically as for the LBC specimens, 
as described below. All HPV tests were performed by laboratory assistants unaware of 
the cytological status and the results from the comparative HPV detection tests.
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HPV detection and genotyping
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment 
assay (HPV SPF10-Line Blot 25; Labo Bio-medical Products BV, Rijswijk, The Netherlands). 
This assay amplifies a 65-bp fragment of the LI open reading frame and allows 
detection of a broad range of high-risk (hr), low-risk (Ir) and possible hrHPV 
genotypes.27
Twenty-eight oligonucleotide probes which recognize 25 different types were tailed 
with poly(dT) and immobilized as parallel lines to membrane strips (Labo Bio-medical 
Products BV, Rijswijk, The Netherlands). The HPV genotypes detectable are hrHPV 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73 and two probable HRHPV types (53 and 
66). Samples that tested positive using the DNA enzyme immunoassay but showed 
no results on the LiPA strip were considered to be HPV "X" type, i.e., genotypes not 
available on the LiPA strip. LrHPV types were defined as HPV types 6, 11, 34, 40, 42,43, 
44, 54, 55, 58, 70, 74, and "X". The HPV genotyping assay was performed as described 
previously.28The LiPA strips were visually inspected and interpreted using the provided 
reference guide.
Study design
All samples were assessed for HPV genotyping using the HPV SPF10-Line Blot 25 assay. 
For the first sample set, the self-sampled material on the FTA cartridge was compared 
to a liquid-based cervical smear obtained for diagnostic purposes by a trained 
physician in the outpatient clinic. Additionally, as HPV DNA elution is a novel method 
to obtain HPV DNA from an FTA Elute cartridge, results of DNA elution were compared 
to results from HPV DNA extraction (Figure 3).
In the second sample set, the self-sampled material stored in liquid-based solution 
was compared to self-sampled material on the FTA cartridge. Again, results of DNA 
elution and extraction from the FTA cartridge were compared (Figure 3). In the original 
study population of sample set 2 (n=2065), detection of (3-globin was used as a control 
for sample sufficiency and showed less than 1% false negatives.
Comparing the presence of hrHPV between the two samples, results were termed 
concordant or discordant based on the following definitions. If analyses showed 
identical genotypes in both samples, the results were termed concordant. Genotyping 
results were termed discordant when no similarities in the genotypesexisted.
This study was approved by the local medical ethics committee. All participants 
provided an informed consent.
Statistics
All data were analyzed using SPSS version 16.0 for W indows (Chicago, Illinois, U.S.A.). 
Agreem ent was measured by absolute agreem ent and Cohen's kappa statistics, a 
measure of the agreement between two methods that is in excess of that due to chance.
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Results
The study group consisted of 96 wom en between 18 and 51 years of age. The results 
of the tw o sample sets are described separately, since sample set 2 consisted of 
healthy unscreened wom en and sample set 1 consisted of wom en with a higher risk 
of an HPV infection than in the general population as they had initially been referred 
to the gynaecologist for cervical follow up for several reasons.
Sample set 1
The median age of the 45 wom en in sample set 1 was 38 years (standard deviation
6.85 years, range 23 to 51 years).
Cervicovaginal self-obtained sample versus physician-obtained cervical smear
O f the 45 self-collected cervicovaginal samples on the FTA cartridges 62.2% (n=28) 
tested positive for one or more HPV genotypes. This high prevalence was expected 
due to the nature of the follow up. O f these 28 samples 25 also tested positive for HPV 
in the cervical smear sample obtained by the physician.
O f the 28 HPV positive samples, 19 samples showed similar types, 5 samples showed 
an additional genotype (sample no. 2, 5, 9,16, and 25) (Table 1), and 4 samples showed 
a different genotype (sample no. 8,10,18, and 20) (Table 1). The overall agreem ent for 
HPV positivity between self-sampling and the cervical smear taken by the physician 
was 93.3% (kappa value, 0.86; 95% confidence interval, 0.713 to 1.013).
Concordance and discordance of hrHPV
Table 1 shows a summary of the genotypes per sample-set as well as the concordance 
and discordance for hrHPV. Taking the samples of all 45 wom en into account, 42 
samples (93.3%) were concordant and 3 samples (6.7%) were discordant for hrHPV 
presence. In these three samples, the physician-obtained smear did not contain a 
hrHPV type in contrast to the self-obtained sample (sample no. 8, 16, and 18) (Table 1). 
O f the 42 concordant samples, 25 showed no hrHPV DNA in both self- and physician- 
obtained samples. In 20 of the 45 (44.4%) self-obtained samples, one or more HRHPV 
types were detected; 17 patients also tested hrHPV positive in the cervical smears 
obtained by the physician. The overall agreement for hrHPV positivity was 93.3% 
(kappa value, 0.86; 95% Cl, 0.713 to 1.013).
Concordance and discordance of IrHPV
In 13 of the 45 (28.9%) self-obtained samples, one or more IrHPV types were detected, 
10 patients also tested IrHPV positive in the cervical smears obtained by the physician. 
The overall agreem ent for IrHPV positivity was 93.3% (kappa value 0.83; 95% Cl 0.635 
to 1.016).
97
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Table 1 HPV detection by SPF10-Line Blot 25 for corresponding genital self-obtained smears and physician-obtained cervical smears 
(sample set 1 )a
Sample no. HPV detection using 
physician-obtained samples (LBC)
HPV detection using 
self-obtained samples (FTA cartridge)
HPV Accordance
DNA extraction hr Ir DNA extraction DNA elution hr Ir hr Ir
1 52 + - 52 52 + - c c
2 51 + - 11,31,51 11,31,51 + + c d
3 18,31 + - 18,31 18,31 + - c c
4 16 + - 16 16 + - c c
5 53 + - 6,53 6,53 + + c d
6 16 + - 16 16 + - c c
7 6 - + 6 6 - + c c
8 N - - 52 52 + - d c
9 16,66 + - 66 66 + - c c
10 N - - 11 11 - + c d
11 16 + - 16 16 + - c c
12 66 + - 66 66 + - c c
13 X - + X X - + c c
14 59 + - 59 59 + - c c
15 39 + - 39 39 + - c c
16 42 - + 18,42 18,42 + + d c
17 16 + - 16 16 + - c c
18 N - - 16 16 + - d c
19 51 + - 51 51 + - c c
20 68, 70 + + 52,70 52, 70 + + c c
21 51 + - 51 51 + - c c
22 X - + X X - + c c
23 6,51,58 + + 6,51,58 6,51,58 + + c c
24 58 - + 58 58 - + c c
25 31 + - 31,51 31,51 + - c c
26 70 - + 70 70 - + c c
27 6 - + 6 6 - + c c
28 X - + X X - + c c
29-45 N N N N N N N c c
ahrHPV types (hr) were 16,16, 31, 33,35, 39, 45, 51, 52, 56, 59, arid 66/73; probable hrHPV types were 53 arid 66. IrH PV tvpe ; (Ir) were 6,11, 34, 40, 42,43, 44, 54, 55, 56, 70, 74, 
and'X. c, concordant results; d, discordant results; N, HPV negative; -, negative; +, positive.
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Table 1 shows a summary of the genotypes per sample-set as well as the concordance 
and discordance for IrHPV. Taking the samples of all 45 wom en into account, 42 
samples (93.3%) were concordant and 3 samples (6.7%) were discordant for IrHPV 
presence. In these three samples the physician-obtained smear did not contain a 
IrHPV type in contrast to the self-obtained sample (sample no. 2, 5, and 10) (Table 1). 
O f the 42 concordant samples, 32 showed no IrHPV DNA in both self- and physician 
obtained samples.
DNA elution versus DNA extraction
As DNA elution is a novel method to obtain DNA from an FTA cartridge, HPV DNA 
from the self-sampled material on the FTA cartridge yielded by DNA elution was 
compared to HPV DNA yielded from the cartridge by DNA extraction. The results 
showed a perfect overall agreem ent of 100% (kappa value, 1.0; 95% Cl, 1.0 to 1.0) 
indicating the reliability of this procedure (Table 1).
Sample set 2
The median age of the wom en in sample set 2 was 21 years (range, 18 to 29 years).
O f the 51 self-collected cervicovaginal samples applied to a liquid-based medium, 13 
(25.5%) tested positive for one or more HPV genotypes. All of these HPV-positive 
samples also tested positive for HPV on the FTA cartridge (Table 2). Moreover, the 
overall agreem ent for HPV positivity between the FTA cartridge and liquid-based 
medium was 100% (kappa value, 1.0; 95% Cl, 1.0 to 1.0).
O f the 13 HPV positive samples, 10 samples showed similar types, 2 samples showed 
an additional genotype (sample no. 9 and 12) (Table 2), and 1 sample showed a 
different genotype (sample no. 13) (Table 2).
Concordance and discordance of hrHPV
Table 2 shows a summary of the genotypes per sample set as well as the concordance 
of hrHPV between the liquid-based and filter-based samples. Taking all 51 samples 
into account, all samples were concordant for hrHPV detection of which 9 (17.6%) 
were hrHPV positive. In these nine liquid-based stored self-obtained samples, one or 
more hrHPV types were detected; all samples (100%) also tested hrHPV positive on the 
FTA cartridges.
Additionally, the overall agreem ent for hrHPV positivity between FTA cartridge and 
liquid-based medium was 100% (kappavalue, 1.0; 95% Cl, 1.0 to 1.0).
Concordance and discordance of IrHPV
One or more IrHPV types were detected in seven of the liquid-based stored 
self-obtained samples (13.7%) versus seven on the FTA cartridges (Table 2). However, 
not all samples showed similar types, resulting in only five concordant IrHPV types.
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The overall agreem ent for LR-HPV positivity between FTA cartridge and liquid-based 
medium was 96.1% (kappa value, 0.83; 95% Cl, 0.609 to 1.059).
DNA elution versus DNA extraction
In sample set 2, HPV DNA yielded from the self-obtained material on the FTA cartridge 
by DNA elution was again compared to DNA yielded from the FTA cartridge by 
extraction. The results showed an overall agreem ent of 100% (kappa value, 1.0; 95% 
Cl, 1.0 to 1.0).
Discussion
HPV testing in cervical cancer screening has a beneficial effect in patient management 
and can increase the success rate of population-based screening programs in reducing 
cervical cancer incidence.3'46'8 Regarding HRHPV testing, cervicovaginal self-obtained 
samples have repetitively been proven to be as reliable as physician-obtained 
samples.15' 16 This present study underlines the reliability of using cervicovaginal 
self-samples for HRHPV testing.
However, despite differences in self-sampling methods, many previous studies have 
used liquid-based sample storage and transport media. Use of these solutions may 
result in a delay or inability to implement at-home self-sampling of population-based 
screening non-responders because of a number of reasons. For example, one reason is 
the high cost due to legislations for these potentially hazardous liquid-based techniques, 
which require difficult and therefore expensive logistics. An alternative for transport of 
potentially hazardous solutions could be storage on filter papers, i.e., FTA cartridges. 
These FTA cartridges, for example, are less prone to contamination and are therefore 
easy to handle. For instance, filters have been used for decades in the postnatal 
screening of certain congenital disorders and diseases. The air-dried samples showed 
stability at room temperature for months, up to years.29 Furthermore, at-home collection 
for HIV testing on filter papers has been considered feasible and acceptable in a high-risk 
cohort. Additionally, also viral load and genotypic resistance assessments in applied 
whole blood and plasma of HIV-positive patients appear to be possible.22 24 
To compare the transport media used in this study, it would be ideal if all conditions 
across the groups were equal. However, as we are particularly interested in whether 
results of HPV detection in cervicovaginal self-obtained samples are comparable to 
the results of HPV detection in physician-obtained cervical smears, the "golden 
standard", despite or precisely because the conditions differ, we think it is important 
to compare the self-sampling method with the "regular" physician-obtained smear as 
a proof of principle. This study shows a high level of overall agreem ent of HPV 
detection and genotyping between physician-obtained cervical smears which are
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applied to a liquid-based and self-obtained cervicovaginal samples that are 
subsequently applied to an FTA cartridge. Additionally, all hrHPV positive physician- 
obtained smears were hrHPV positive in the cervicovaginal self-samples as well. 
Besides the reliability of the FTA cartridge regarding hrHPV testing, its unique 
properties make it easy to handle. For instance, the air-dried FTA cartridges showed 
stability at room temperature for months. Furthermore, the uncertainty about 
performing the self-sampling procedure properly will be overcome since the 
indicating FTA cartridge has an indicating dye which changes upon application of the 
sample. Furthermore, the contamination risk is reduced as the virus is denatured upon 
application, making it biohazard free and safe for transport by mail. This allows cervical 
or self-obtained genital samples to be added on this FTA cartridge and sent to 
designated central laboratories for analysis. Even more important, by using the FTA 
cartridge, processing costs will be low as DNA is eluted by a simple method using 
only water and heat, w ithout requiring expensive DNA extraction. Besides the use in 
existing screening programs, usage of the FTA cartridge could simplify the introduction 
of organized HPV-based cervical screening programs in developing countries as well. 
It has been shown that self-sampling methods are unsuitable for cytological analysis.9
12 To complete the diagnosis for the individual HRHPV positive patient a subsequent 
physician-obtained smear ought to be performed. Preferably, this is done solely in 
wom en who are persistently HRHPV positive. W hether the self-sampling wom en are 
willing to have an additional cytology smear taken in case of HRHPV persistence has 
not yet been studied.
Since cervicovaginal self-sampling could be an easy accessible and user-friendly 
method, wom en not participating in the screening program due to fear or other 
reasons might be interested to actually participate since this technique could be 
applicable to at-home self-sampling. Therefore, the introduction of cervicovaginal 
self-sampling will probably increase the participation rate.9 lft 1218 Recently, Bais et al. 
showed that the active response to self-sampling in populations-based screening 
nonresponders was significantly higher than the active response to an extra recall for 
conventional cytology.21
For HPV detection and genotyping we used the HPV SPF10-Line Blot 25. This assay has 
previously shown high concordance with various other systems.26'28 This indicates the 
suitability of the FTA cartridge for various other HPV detection and genotyping systems 
like the Roche Amplicor and linear array assays. Preliminary studies indeed showed an 
excellent concordance (data not shown). However, further study may be needed to 
assess genital self-sampled FTA cartridges using other commercially available HPV 
detection tests with lower analytical sensitivity (e.g. hybrid capture 2). Additionally, 
since this was a pilot study and sample sizes were small further research should be 
conducted. Furthermore, since not all samples were checked for specimen sufficiency, 
i.e. (3-globin, future research should include a measure for sample sufficiency.
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In conclusion, the results of HPV detection and genotyping on self-sampled 
cervicovaginal samples using a Rovers Viba-brush and the Whatm an indicating FTA 
elute cartridge are highly representative for the cervical HPV status.
Furthermore and equally important, this study shows that elution of DNA from the 
Whatm an indicating FTA elute cartridge, w ithout the necessity of DNA extraction 
procedures, is a fast, cheap, and reliable method. The Whatm an indicating FTA elute 
cartridge technique is a convenient medium for collection, as the colour of the FTA 
cartridge changes after application of the self-sampled material confirming proper 
use. Additionally, the FTA cartridges can be stored at ambient temperature for months, 
and since the method is non-hazardous, the samples are allowed to be sent by regular 
mail. This suggests that this method might be applicable to at-home self-sampling in 
population-based screening nonresponders, as well as for the introduction of primary 
HPV-based cervical cancer prevention, and for establishing cervical cancer screening 
programs in developing countries.
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CHAPTER 7
Abstract
Background. The clinically validated hrHPV Hybrid Capture (HC2) and GP5+/6+-PCR 
assays were analyzed on an Indicator FTA elute cartridge (FTA cartridge). The FTA 
cartridge is a solid dry carrier, which allows safe transport of cervical samples. FTA 
cartridge samples were compared to liquid-based samples in terms of hrHPV and 
high-grade cervical intraepithelial neoplasia (high-grade CIN) detection.
Methods. One cervical sample was collected in a liquid-based medium and one was 
applied to the FTA cartridge. DNA was eluted directly from the FTA cartridge by a 
simple elution step. HC2 and the GP5+/6+-PCR, were performed on both the 
liquid-based and the FTA eluted DNA of 88 women.
Results. Overall agreement between FTA and liquid-based samples for the presence 
of hrHPV was 90.9% with GP5+/6+-PCR and 77.3% with HC2. The sensitivity for 
high-grade CIN of hrHPV testing on the FTA cartridges was 84.6% with GP5+/6+-PCR, 
and only 53.8% with HC2. By comparison, these sensitivities on liquid-based samples 
were 92.3% and 100% for GP5+/6+-PCR and HC2, respectively.
Conclusions. The FTA cartridge shows a reasonably good overall agreem ent for 
hrHPV detection with liquid-based media when using GP5+/6+-PCR, but not for HC2 
testing. Even with GP5+/6+-PCR, the FTA cartridge is yet not capable of detecting all 
high-grade CIN lesions.
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Introduction
Infection with human papillomavirus (HPV) is indicated as the causal role in cervical 
cancer development. Primary high-risk (hr) HPV screening appeared to be more 
sensitive than cytology in detecting cervical intraepithelial neoplasia grade 2 or worse 
(CIN2+), and therefore, displays a superior protection against cervical precancer and 
cancer.12 Interestingly, material from cervicovaginal lavages or cervicovaginal brushes 
proved to be highly representative for the cervical hrHPV status.3 8 Moreover, analysis 
of cervicovaginal self-samples appears to be as reliable as physician-obtained samples 
for detecting cervical (pre)malignant disease following hrHPV analysis.910 
Screening via self-samples obtained in the privacy of women's own homes, is likely to 
result in a better attendance than screening via samples obtained by physicians or 
other healthcare providers.11'12 Cervicovaginal self-sampling is therefore an attractive 
alternative for physician-obtained cervicovaginal material.5' 12
Most previous studies used cervical samples with liquid-based collection systems.211' 
u.u-16 |n principle, the use of liquid-based self-samples has the impractical consequence 
that fluids may leak, and special precautions have to be taken for transport. In case 
alcohol-containing preservation fluids are used, it may cause problems like 
inflammability and harm to eyes and skin. These problems may be circumvented 
when applying self-sampled specimens to a solid dry carrier, the Whatman indicating 
FTAelute cartridge (FTA cartridge). FTA cartridges are biohazard free, as the sample is 
denaturized upon application. These properties solve storage and transport problems 
often seen with liquid-based samples. Importantly as well, the FTA cartridge has an 
indicating dye that changes from purple to white when a sample is applied, thereby 
confirming that wom en performed the procedure properly. This solid dry carrier 
might be beneficial for specimens collected by non-physicians in remote areas, which 
would need transportation to the laboratories. W e previously performed a proof-of- 
principle study to assess the potential of HPV detection directly on eluted DNA from 
the FTA cartridge. In order to do so, we used the SPF -Line Blot 25 assay and found a 
98% agreem ent with physician-obtained samples.17 However, the SPF10-Line Blot 25 
assay is known to be very sensitive in HPV detection, and it is unknown how clinically 
validated hrHPV assays with a lower analytical sensitivity would perform on FTA 
cartridge samples. In this study, we evaluated the clinically validated Hybrid Capture 
2 (HC2) and GP5+/6+-PCR1,2, methods on physician-obtained cervical samples applied 
to the FTA cartridge for the detection of hrHPV and cervical premalignancies in 
wom en visiting a gynaecologic outpatient clinic.
CHAPTER 7
Materials and Methods
Study subjects
Between June and December 2009, 94 wom en were recruited at the department of 
Obstetrics and Gynaecology of the Radboud University Nijmegen Medical Centre, 
The Netherlands. The cohort consisted of women with different risk factors for HPV 
infection and CIN. All women visited the gynaecologist at the outpatient department. 
Two cervical samples, for liquid-based and cartridge collection, respectively, were 
obtained as specified below. The volume of liquid-based samples of six women was 
insufficient to perform the two different hrHPV tests in addition to liquid-based 
cytology. These women were therefore excluded. The remaining 88 patients constituted 
the study population.
Sample collection
Two Cervex-brushes® (Rovers Medical Devices B.V., Oss, The Netherlands) were used 
to obtain the cervical samples. The first brush was rinsed in a ThinPrep vial (Cytyc 
corp. Boxborough MA, USA) on which regular liquid-based cytological examination 
and HPV testing by HC2 and GP5+/6+-PCR was performed. The second brush was 
applied to the FTA cartridge (Whatman indicating FTA elute cartridge, GE Healthcare, 
United Kingdom), as described previously.17 Again HC2 and GP5+/6+-PCR HPV testing 
was performed on the DNA eluted from these FTA cartridges.17 
In order to assess the samples anonymously, all FTA cartridge samples and cervical 
liquid-based samples were labeled with a unique patient code before sending them 
to the laboratory. Histology results were retrieved from the medical records in case 
the cervix was biopsied during colposcopy or in case of surgery. Histology results 
were considered superior to cytology results.
Liquid Based samples
All ThinPrep vials were used for regular cytological examination. Papanicolaou smear 
abnormalities were interpreted and classified by using the Bethesda system.
For the HC2 assay, 5ml_ liquid-based homogenized medium was used according to 
the manufacturer's instructions (Qiagen, Gaithersburg, USA).
For the hrHPV GP5+/6+-PCR, DNA was isolated out of 500 pL medium of the 
liquid-based cervicovaginal samples, using the MagNAPure LC Isolation station (Roche 
Diagnostics GmbH, Roche Applied Science, Mannheim, Germany). Nucleic acid was 
resuspended in a final volume of 50pL; 10 pL was used for the GP 5+/6+-PCR analysis, 
as previously described.19 20
FTA cartridges
The indicating FTA elute matrix contains an indicating dye that changes from purple to
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white upon application of a colourless sample such ascervicovaginal swab. The white parts 
on the FTA cartridges were punched using a sterilized perforator specifically designed for 
the FTA cartridges (3mm Harris Uni-Core device; Whatman). DNA was recovered from the 
FTA elute matrix through a simplified elution process using heat and water. Inhibitory 
components, such as haemoglobin, are retained on the FTA elute matrix.
For elution, four 3mm punches from the matrix were transferred into a 2.0-mL microfuge 
tube, 2.0ml_ of sterile H,0 was added to the punches and immediately pulse vortexed 
three times, for a total of 5 seconds. The H,0 was removed with a sterile fine tip pipette. 
An amount of 75|_il_ of sterile H,0 was added to the punches and the tube was transferred 
to a heating block at 95°C for 30 minutes. At the end of the incubation period the sample 
was removed from the heating block and pulse vortexed approximately 60 times. 
Subsequently, the tube was centrifuged for 30 seconds and the supernatant with eluted 
DNA was transferred to a new microcentrifuge tube. The eluted DNA was stored at -80°C 
for further use. Finally, according to protocol, 10|_il_ of the eluate was used for the 
GP5+/6+-PCR analysis, and 50|aL for HC2 analysis.
HPV detection by Hybrid Capture 2 and GP 5+/6+-PCR
Five ml_ of liquid-based homogenized medium and separately 50|ul eluted DNA from 
the cartridges were used for the HC2 according to the manufacturer's instructions. 
The HC2 assay included a mixture of probes for the HPV types: 16,18, 31, 33, 35, 39,45, 
51, 52, 56, 58, 59, and 68. RNA:DNA hybrids were captured with antibodies and a 
secondary signaling antibody created a chemiluminicent signal that was ultimately 
expressed as relative light units per cut-off value (RLU/CO), representing the ratio 
between the emission from a sample to the average of three positive controls (i.e., 1 
pg/mL of cloned HPV 16 DNA). Samples were considered HC2 positive in case of an 
RLU/CO value > 1.0 (equivalent to signal of 1 pg/mL HPV 16 DNA). Repeat testing is 
recommended for RLU/CO ratios between 1.0 and 2.5. As priority was given to clinical 
testing, in the context of this study material was limited. Therefore, the primary test 
result was considered definitive.
Separately, 10|jL isolated DNA from the liquid-based specimens and the 10|jL DNA 
eluted from the FTA cartridges, were used for HPV testing by the GP5+/6+-PCR assay. 
The GP5+/6+-PCR was performed, using the enzyme immunoassay (EIA) readout 
system with a probe cocktail of 14 hrHPV types (i.e. HPV 16,18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68) as described previously.19 20 The standard cut off value of three 
times the mean OD value of the PCR-negative controls was used .2C’ 21
Statistics
All data were analyzed using SPSS version 16.0 for Windows (Chicago, Illinois, U.S.A.). 
Agreement was measured by absolute agreement and Cohen's kappa statistics, a measure 
of the agreement between two methods that is in excess of that due to chance.
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Results
The study group consisted of 88 wom en with a median age of 37 years of age (SD 10 
yrs, range 24 to 72 yrs). In 18 of the 88 cases, histological specimens of the cervix were 
obtained. Histology was indicated by a liquid-based cytology result of at least 
low-grade squamous intraepithelial lesion (LSIL). However, in 10 LSIL cases no biopsies 
were taken because of a non-suspicious colposcopy. Four of the 18 histological 
specimens showed normal tissue, one showed a low-grade CIN lesion (ClN1), and 13 
specimens showed a high-grade CIN lesion (CIN2-3). In total, the cervical samples 
were within normal limits (WNL) in 46 cases (52.3%), atypical cells with undetermined 
significance (ASC-US) in 18 cases (20.5%), and in 24 cases (27.3%) the smear appeared 
to be LSIL or more severe.
GP5+/6+-PCR
Table 1 shows that in 32 of the 88 (36.4%) liquid-based samples, hrHPV was detected 
using GP5+/6+-PCR. By comparison, thirty of the 88 (34.1%) FTA cartridge eluted DNA 
samples, were hrHPV positive with GP5+/6+-PCR. Twenty-seven of the 32 (84.4%) 
GP5+/6+-PCR positive liquid-based samples by GP5+/6+-PCR showed concordant 
hrHPV positive results on the eluted DNA from the corresponding FTA cartridge 
samples. Five wom en had GP5+/6+-PCR positive liquid-based samples but negative 
FTA cartridge samples. Two of these five wom en had normal cytology, two wom en 
had LSIL cytology and one woman had a histological CIN3 lesion. In three wom en 
hrHPV was detected on the eluted DNA from the cartridge but was found negative on 
the liquid-based samples with GP5+/6+-PCR. One of these wom en had a normal 
cytology result, the other two had ASC-US. In the total group of 88 samples, 80 FTA 
cartridge samples showed concordant hrHPV test results with the liquid-based 
samples (concordance 90.9%, kappa 0.80, Cl 0.67-0.93) when the GP5+/6+-PCR was 
used for detection (Table 2).
There were 13 histologically confirmed high-grade CIN lesions. The liquid-based 
samples of 12 of these 13 lesions were hrHPV positive by GP5+/6+-PCR analysis 
(sensitivity 92.3%). The FTA cartridges showed 11 hrHPV positive samples by 
GP5+/6+-PCR analysis (sensitivity 84.6%).
Hybrid Capture 2
Using the HC2 for the detection of hrHPV, 41 of 88 (46.6%) liquid-based samples were 
found positive (Table 1). These positive samples included all samples with high-grade 
CIN (sensitivity 100%). Of the positive samples, only 21 were also found positive with 
HC2 using the eluted DNA from the FTA cartridge samples. Fifty-four of the 67 wom en 
with a negative FTA cartridge sample, had a normal or ASC-US cytology result, and 
four had a normal histology result. However, 6 out of 13 HC2 hrHPV liquid-based
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positive wom en with hystologically confirmed high-grade CIN lesions were missed 
using the HC2 on eluted DNA (sensitivity 53.8%). The mean RLU/CO of the FTA cartridge 
samples detected with four punches was rather low (mean 33.1, SD 63.9), compared to 
the corresponding RLU/CO of the liquid-based samples (mean 225.3, SD 296.7). Indeed,
13 out of the 20 hrHPV positive liquid-based samples with a negative result on the FTA 
cartridge samples had a low RLU (less than 10).
In 68 of the total 88 samples, concordant hrHPV HC2 results were found between the 
liquid-based samples and the FTA cartridge samples (concordance 77.3%, kappa 0.53, 
Cl 0.37-0.69) (Table 2).
GP5+/6+-PCR vs Hybrid Capture 2
Only one liquid-based sample was negative by HC2 but positive by GP5+/6+-PCR 
(sample no. 19). This was a LSIL sample. Ten liquid-based samples were positive with 
HC2 but negative with the GP5+/6+-PCR (sample no. 1, 3, 5, 7,10,11,13,14, 22, and 30). 
The majority (8 out of 10) of these HC2 positive but GP5+/6+-PCR negative liquid-based 
samples were within the normal cytology or histology group (4 samples) or ASC-US (4 
samples) group. One high-grade CIN lesion (i.e. CIN2) positive by HC2 on liquid was 
negative by GP5+/6+-PCR on liquid (sample no. 30). Absolute agreem ent between 
the two hrHPV tests was 87.5% (kappa 0.75, Cl 0.61-0.88) for the liquid-based samples 
(Table 2).
All FTA cartridge samples that were positive with HC2 were also positive with the 
GP5+/6+-PCR. Nine FTA cartridge samples were negative with HC2 but positive with 
GP5+/6+-PCR (sample no. 2, 7, 10, 11, 12, 33, 34, 40, and 42). These comprised samples 
were cytologically classified as W NL (n =2), ASC-US (n=3), or histologically as CIN2 (n=1), 
or CIN3 (n=3). Absolute agreem ent between the two hrHPV tests was 89.8% (kappa 
0.76, Cl 0.61- 0.90) for the FTA cartridge samples (Table 2).
Table 1 and 2 show a summary of the hrHPV results of the HC2 and GP5+/6+-PCR 
tests of both the liquid-based and the FTA cartridge samples, as well as the 
concordances.
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Table 1 Liq uid-based and FTA cartridge samples analyzed with the two different hrHPV assays (HC2 and GP5+/6+-PCR), with 
according cytology/histology
liquid-based samples FTA cartridge samples
cytology histology HC2
(RLU/CO)
GP5+/6+-PCR HC2
(RLU/CO)
GP5+/6+-PCR
1 W N L - 1.23 neg neg neg
2 W N L - 1.23 pos neg pos
3 W N L - 2.91 neg neg neg
4 W N L - 2.93 pos neg neg
5 HSIL normal 4.50 neg neg neg
6 W N L - 8.98 pos neg neg
7 W N L - 76.00 neg neg pos
8 W N L - 213.00 pos 16.24 pos
9 LSIL normal 783.58 pos 2.61 pos
10 ASC-US - 1.09 neg neg pos
11 ASC-US - 1.45 neg neg pos
12 ASC-US - 2.99 pos neg pos
13 ASC-US - 4.36 neg neg neg
14 ASC-US - 95.00 neg neg neg
15 ASC-US - 460.00 pos 19.41 pos
16 ASC-US - 543.00 pos 218.43 pos
17 ASC-US - 635.00 pos 34.83 pos
18 ASC-US - 737.00 pos 140.70 pos
19 LSIL - neg pos neg neg
20 LSIL - 2.24 pos neg neg
21 LSIL - 2.73 pos 1.47 pos
22 LSIL - 13.59 neg neg neg
23 LSIL - 35.92 pos 4.49 pos
24 LSIL 196.00 pos 6.38 pos
25 LSIL 238.94 pos 2.61 pos
26 LSIL - 318.00 pos 185.67 pos
27 LSIL - 552.60 pos 10.34 pos
28 LSIL - 771.27 pos 1.37 pos
29 ASC-US CIN 1 4.74 pos 4.94 pos
30 LSIL CIN2 11.15 neg neg neg
31 L7HSIL CIN2 13.40 pos 1.73 pos
32 I7HSIL CIN2 73.19 pos 1.43 pos
33 ASC-US CIN2 1085.49 pos neg pos
34 HSIL CIN3 1.34 pos neg pos
35 HSIL CIN3 1.90 pos neg neg
36 HSIL CIN3 27.07 pos 18.28 pos
37 HSIL CIN3 100.75 pos 4.20 pos
38 ASC-US CIN3 108.72 pos 3.04 pos
39 HSIL CIN3 294.65 pos 8.12 pos
40 HSIL CIN3 422.95 pos neg pos
41 HSIL CIN3 467.28 pos 8.85 pos
42 HSIL CIN3 794.08 pos neg pos
43-79 W N L -* neg neg neg neg
80-88 ASC-US - neg neg neg neg
WNL, within normal limits; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous 
intraepithelial lesion; CIN, cervical Intraepithelial neoplasia 
* = two times confirmed by histology 
b o ld  = positive result
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Discussion
W e aimed to assess whether the clinically validated HC2 and GP5+/6+-PCR systems 
could be performed on the FTA cartridge material to detect high-grade CIN lesions. 
W e found a reasonably good concordance in hrHPV detection between liquid-based 
and FTA cartridge systems, when using the GP5+/6+-PCR. This concordance was 
much lower using HC2. Moreover, the sensitivity of hrHPV detection on the FTA 
cartridge for high-grade CIN lesions was 84.6% with GP5+/6+-PCR but only 53.8% 
with HC2.
Although more liquid-based samples were hrHPV positive with HC2 than with 
GP5+/6+-PCR (41 versus 32, respectively), only 21 of the 41 FTA cartridge samples 
were hrHPV HC2 positive. A possible explanation for this is that the amount of DNA 
eluted from the punches is insufficient to allow reliable HC2 testing, a method which 
does not use a target amplification. Optimization of the processing steps, for example 
by increasing the number of punches, may improve the HC2 outcome. However, 
increasing the number of punches is labor-intensive and the H ,0  volume used needs 
to be increased equivalently. Additionally, we used the accepted RLU/CO values of 1.0 
for signifying a positive HPV HC2 test. This is arbitrary because these values were 
developed and validated in conjunction with liquid-based tests. It might be possible 
that values below 1.0 RLU/CO represent positive test results when other media and 
different amounts of DNA are used. Moreover, results with RLU/CO values between 1.0 
and 2.5 are not repeated within this study as recommended according to protocol. 
Because priority was given to clinical tests, there was limited availability of sampled 
material. These samples could have been negative with repeat testing.
Based on the results so far, HC2 might not be the preferred method for hrHPV 
detection using FTA cartridges. To obtain sufficient (clinical) sensitivity, amplification 
based methods might be more suitable. W e previously reported our results for the 
FTA cartridge with the SPF -Line Blot 25.17 W ith an overall agreem ent for hrHPV 
between the FTA cartridges and the liquid-based samples of 98% (kappa 0.94), the 
SPF10-Line Blot 25 proved to be a highly reliable method for hrHPV testing on the FTA 
cartridges. Additionally, Gustavsson et al. reported an agreem ent in hrHPV positivity 
between the cytobrush and FTA samples of 94% (kappa 0.88, 95% Cl 0.748-1), again by 
using a (real-time) PCR-based assay.22 Though, the results of the clinically validated 
GP5+/6+-PCR in this study are promising but do not completely confirm previous 
findings on PCR based hrHPV testing on FTA cartridges.
Because the sensitivity of detecting hrHPV and high-grade cervical lesions on the FTA 
cartridge is still not sufficient, there are aspects that need further consideration. 
Transferring a sample collected with a sampling device onto the surface of a solid 
sample carrier such as the FTA cartridge, might run into the same problems that 
plagued the conventional Papanicolaou test (i.e., not all cells collected are transferred
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but remain on the sampling device). This may result into a non-representative sample. 
Moreover, in case of high-grade CIN, the HPV copy number per cell tends to be lower 
as the HPV tends to be integrated. Especially then, showing that the sample contains 
DNA does not necessarily mean that the HPV-infected cells are transferred to the FTA 
cartridge. Previous studies have shown that cells from dysplastic cervical lesions are 
more likely to show aberrant expression of adhesion molecules, and might fail to 
exfoliate. Similarly, such cells might be relatively less likely to be transferred to a solid 
substrate like the FTA cartridge.
Given the cross-sectional nature of this study, only 18 wom en had a histological 
specimen. W om en who do not have colposcopically detectable lesions, whether or 
not they are hrHPV positive, are not usually subjected to blind biopsies. These biopsies 
would be highly unlikely to show significant pathology.
Furthermore, only physician-obtained cervical samples were used in this study in 
order to enable an optimal comparison between liquid-based and FTA cartridge 
samples. The aim of this study was to compare the use of tw o collection methods, i.e., 
FTA cartridge versus liquid-based, and to avoid any influence from sampling different 
sides. Therefore, only physician taken cervical samples were analysed. For self-sampling, 
cervicovaginal rather than solely cervical samples are brushed. Consequently, no 
direct applicability of this study to self-sampling is legitimate. Additionally, the fact 
that the tw o Cervex brushes were taken consecutively because of diagnostic reasons, 
might have induced a bias against the FTA cartridge method. The second brushes 
were used for the FTA cartridges. Most of the relevant material might already have 
been sampled by the first brush.
This study concerns a population of wom en who visited the gynaecologic outpatient 
department and consequently involved a HPV high-risk group. Therefore, in order to 
consider the use the FTA cartridge in a screening population, a thorough analysis of 
the FTA cartridge in such a population is necessary.
Nevertheless, our data have shown that in the context of GP5+/6+-PCR, but not HC2 
testing, the FTA cartridge holds promise as collector of cervical specimens for 
screening. However, a ultra-highly or highly sensitive method for HPV detection, such 
as PCR-based HPV DNA testing is required. The clinical implication of those tests must 
be assessed further. The sensitivity is still not equal to that of hrHPV testing by HC2 on 
ThinPrep vials, so further optimization is recommended.
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FIN AL CO N SID ER A TIO N S
There are several ways to optimize cervical cancer prevention, but the actual efficacy 
of the cervical cancer screening programme mainly depends on the invited cohort, 
initial participation, and adherence to subsequent follow-up. All interventions aimed 
to improve the detection of cervical abnormalities are of minimal significance if the 
intervention itself reduces the attendance rate. It is therefore of the utmost importance 
that every alteration of the current guidelines is weighed against the expected 
influence on attendance rate.
Cervical cancer screening, the next 20 years
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step 
process of cervical carcinogenesis. It is considered that the developm ent of cervical 
cancer from the onset of an initial hrHPV infection will take at least 10 years.1 HPV 
vaccination programmes with Cervarix™ (GlaxoSmithKline, Inc) started in the 
Netherlands in 2009. This vaccine against the two most common causative viral 
agents for cervical cancer, has been shown to be highly effective. Vaccination is 
expected to reduce the incidence of cervical carcinoma by 70%.2 It will take about 20 
years before the vaccinated girls will reach the target age for screening, although 
catch-up vaccination will partially reduce this interval. A reduction of cervical cancer 
burden is therefore not expected within a short period of time. Screening remains an 
important manner to prevent cervical cancer for at least 20 years.
Primary hrHPV testing is supposed to be the next rational step in the national cervical 
cancer screening programme, as HPV infection precedes cytological abnormalities. 
An important advantage of hrHPV testing is that it is far more objective and gives 
highly reproducible results compared to cytological screening. HrHPV testing has a 
higher sensitivity than cytological screening to detect cervical abnormalities, but has 
a slightly lower specificity. Incorporating repeat testing in the screening algorithm for 
wom en who are hrHPV positive, increases specificity, and differentiates between 
transient and persistent infections. Only wom en with a persistent hrHPV infection, 
and therefore with a higher risk of cervical abnormalities, should be referred to the 
gynaecologist for cytology and colposcopy. Another way to distinguish HPV infections 
that are potentially more carcinogenic, is making use of biomarkers. For example, 
testing for histological or other biomarkers after a positive HPV result may combine 
both high sensitivity and high specificity. Detection of biomarkers seems to be more 
objective and reproducible than cytological screening as well.
Should hrHPV testing be implemented irrespective of genotype, or should genotyping 
be incorporated in the screening programme? Recently, a Danish study proposed risk 
stratification algorithms depending on HPV type to assist clinicians in estimating 
present and future risk of cervical lesions.2 Information about hrHPV type-specific 
infections makes it possible to distinguish more specifically between transient and 
persistent infections. Every HPV infection has its type dependent clearance and its
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type dependent carcinogenetic characteristics. Infection with the HPV types 16, 18, 
31, and 33, and especially persistent HPV type 16 infection are associated with high 
absolute risks for progression to high-grade cervical lesions.3 This suggests that 
genotyping does haveadditional benefitsand enables patient-centred care. Follow-up 
strategies after genotyping may therefore be adapted to the individual patient.
Screening guidelines may as well be adapted to the changes in incidence of cervical 
cancer in the different age cohorts. There seems to be a rising incidence of cervical 
carcinomas under the age of 30.4 This is correlated with a decreasing age of first sexual 
intercourse, and therefore, a decreasing age of initial HPV infections.5 Fifty percent of 
wom en born between 1979 and 1983, had first sexual intercourse before the age of 
17.6 In case an initial HPV infection is potentially carcinogenic, it will take at least ten 
years to progress into cervical cancer. Consequently, ten years after first sexual 
intercourse and subsequently initial infection with hrHPV, the first cervical carcinomas 
may occur. Therefore, the onset of cervical cancer screening at the age of 30 might be 
relatively late.
In this thesis we reported that 33% of the wom en with cervical cancer were diagnosed 
outside the target age range. One-third of these wom en were diagnosed under the 
age of 30. Of the wom en diagnosed before they were eligible for screening, 80% was 
diagnosed between 27 and 30 years of age. An additional 8%  was detected at their 
first screening round. If the target age-range of the screening programme would be 
lowered from 30 to 27 years, these wom en could have been detected in an earlier 
stage of cervical cancer or even with premalignant disease.
By implementing new screening algorithms, it is essential to take the various 
incidences of histologically different cervical cancers into account as well. The last 
decades, there is an overall decrease of squamous cell carcinomas.7 Though, the 
absence of an overall decrease in adenocarcinoma incidence suggests that the current 
screening programme may not prevent adenocarcinomas as effectively as squamous 
cell carcinomas. Adenocarcinomas do not have as well-defined precursor lesions, as 
squamous cell carcinomas. In younger wom en relatively more adenocarcinomas are 
detected. These are located in the endocervix, and therefore not easily detected by 
cytological screening. Adenocarcinomas are mostly caused by HPV 18, which is then 
present throughout the cervicovaginal tract. In the last decades, even an increase of 
adenocarcinomas in young wom en is seen. Consequently, only lowering the age 
range of the national screening programme with regular cytological screening, will 
not completely solve this issue. Implementing primary hrHPV screening may detect 
more wom en with adenocarcinomas in this young cohort.
However, it is exactly this young cohort that has the highest rate of clinically irrelevant 
transient HPV infections. Around 20% of the wom en between 25-30 are HPV positive.6 
It is therefore essential to search for a balance between the optimal detection of
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cervical cancer precursors, including adenocarcinomas, and the prevention of 
overtreatment. A possible screening algorithm might be a onetime cytological 
screening with a high specificity at the age of 27 to prevent overtreatment, and 
successive hrHPV screening from the age of 30. However, adenocarcinomas will still 
be overlooked. Adding HPV 16/18 testing to cytological screening at the age of 27 
may combine high specificity and the detection of most adenocarcinomas. Primary 
hrHPV screening from the age of 27 may be an alternative algorithm. Though, the 
percentage of hrHPV positive wom en at that age is approximately 30%.6 It is therefore 
important, to set strict guidelines for triage with repeat hrHPV testing, cytology, and 
possibly biomarkers. In case of two consecutive hrHPV negative tests at the age of 27 
and 30, the screening interval may safely be extended to ten years.
Primary HPV testing by using cervicovaginal self-sampling may offer additional 
advantages. W om en who do not respond to invitations for cytological smears may be 
inclined to respond to a self-sampling method.810 As more than 50% of wom en 
diagnosed with cervical cancer have no history of participation in cervical screening, 
additional participation of these wom en implies net profit.1112 A self-sample, however, 
must meet women's wishes and preferences to achieve a high attendance rate. Future 
research addressing whether these self-samples may also be used as primary screening 
tool for all wom en eligible for cervical cancer screening, is necessary. The attendance 
rate achieved by the use of self-samples must reach at least the current attendance 
rate with cytological screening. Adjusted to individual needs, wom en should be given 
the choice, whether to use the HPV self-sample themselves, or to let HPV sampling be 
performed by their general practitioners.
Once wom en are referred for colposcopy and successive treatment after an abnormal 
smear result, there are additional stages in clinical care where improvements are 
possible. Exposing these possibilities starts with awareness. In this thesis we reported 
about the association between (pre-)malignancies, related to hrHPV. W om en with 
HPV related vulvar cancer more often had abnormal cervical lesions. The awareness 
that hrHPV infections might consecutively lead to more than one (pre)malignancy, 
will improve the examination of the female ano-genital tract, and subsequently 
increase the detection of other HPV related (pre)malignancies.
Furthermore, the awareness of the high anxiety that cervical cancer screening evokes, 
makes it possible to interact and implement interventions to decrease this anxiety. We 
showed, in accordance with other studies, that additional written and verbal 
information about HPV and colposcopy, did not reduce anxiety before colposcopy.1315 
It is therefore not sensible to implement such a time-consuming intervention in 
current clinical management. Visual information supply, for example by means of an 
internet link to a video about the colposcopy clinic and procedure, might reduce this
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anxiety.16 Additional research concerning these different interventions, would further 
increase knowledge to optimize clinical management before and during colposcopy. 
One step further in the process of cervical cancer prevention, is the subsequent 
follow-up and/or treatment of cervical (pre-)malignancies. Besides wom en with 
high-grade CIN lesions or cervical cancer, the screening programme will also detect 
wom en with low-grade CIN lesions that may never evolve into invasive cancer. In 
order to avoid overtreatment, it is important to minimize invasive treatment and allow 
these lesions to go into regression. Therefore, it is important to adjust follow-up and 
treatment strategies to the individual patient, where possible. W e showed that it is 
safe to support a less aggressive follow-up strategy in case of lesions suspect for 
low-grade CIN. A less aggressive follow-up strategy, however, requires more time to 
reach normalization of cervical lesions. Psychological burden (e.g., high anxiety levels), 
an active desire to bear children, an IVF treatment course, or the uncertainty if a 
patient will adhere to subsequent conservative follow-up, are reasons to aim for faster 
normalization of cervical lesions. A more aggressive treatment strategy might then be 
preferred.
Cervical cancer screening, more than 20 years from now
The girls that are currently vaccinated against HPV, will reach the screening age after 
approximately 20 years. Therefore, screening programmes need to be reassessed, to 
ensure that cost-effective screening continues in vaccinated populations with low 
disease prevalence. Although the currently used vaccine is highly efficacious, it does 
not protect wom en against all hrHPV types. Moreover, the attendance to vaccination 
in a general population will vary. Vaccination coverage is currently relatively low but 
will probably increase in time. However, vaccination coverage will never reach 100%. 
A vaccine with a cocktail of multiple hrHPV types may achieve a reduction in carcinoma 
incidence even up to 85%. That raised the question if screening for cervical cancer 
remains necessary and cost-effective, 20 years from now.
It is important to increase knowledge about HPV vaccination and the remaining risks 
of cervical cancer despite vaccination. W om en should be well informed that the 
vaccine does not contain all hrHPV types, and may not fully protect individuals against 
cervical cancer. Although the prophylactic vaccines haven shown cross-protection for 
other HPV genotypes than originally designed for, even the protection for the targeted 
types cannot expected to be absolute.17 Furthermore, it is not clear whether 
replacement of hrHPV types will occur, as other hrHPV types now get the opportunity 
to evolve. W ith a decreased incidence, and a subsequently expected lower awareness 
of the consequences of cervical cancer, it is necessary to lower the threshold to 
participate in population-based screening. HrHPV self-sampling may provide that 
lower threshold in the future. To ensure cost-effective screening in this vaccinated 
cohort, screening by HPV self-samples four times a lifetime may be a justified option.
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As the developm ent of cervical cancer from the onset of an initial hrHPV infection is 
generally believed to take at least 10 years, in case of negative hrHPV testing, 
self-sample kits may be sent to wom en at the ages of 27, 30, 40, and 50.
Cervical cancer screening will continue to play an important role in cervical cancer 
prevention for the next 20 years, although algorithms may be altered to achieve the 
maximum benefit. Approximately 20 years from now, the first vaccinated girls will 
reach the screening age. Cervical cancer screening must be adjusted to the vaccinated 
cohort. It is therefore essential that screening guidelines will be regularly re-evaluated 
and adjusted to the current situation and knowledge.
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SUMMARY
Summary
Chapter 1
Cervical cancer screening in the Netherlands was implemented on a national level in 
1988. Currently, wom en between the ages of 30 and 60 are invited for a cytological 
smear every five years. Depending on the smear result, wom en are referred to the 
gynaecologist for colposcopy, are invited fora repeat smear after 6 months, or wom en 
are going back into the screening programme and receive the next invitation after 
five years. The incidence and mortality rate of cervical cancer decreased substantially 
after the introduction of the screening programme.
Chapter 1 gives an overview of the history of cervical cancer screening in the 
Netherlands, and chronologically describes the potential failures and pitfalls of 
cervical cancer screening. The effectiveness of cancer screening in the reduction of 
incidence and mortality depends on the age-range of the target cohort, participation 
rate of the invited population, sensitivity of the screening test, frequency of screening, 
compliance to follow-up, and effectiveness of early treatment.
Chapter 2
This chapter describes the detected shortcomings of the current screening programme 
by retrospectively assessing the screening histories of wom en with cervical cancer. 
Screening histories of 401 wom en diagnosed with cervical cancer were studied. 
Two-third of these wom en were diagnosed within the target cohort (age 30-60), and 
received at least one invitation of the national screening programme. One-third of the 
wom en with cervical cancer were diagnosed outside the target age-range of the 
screening programme. Of the wom en within the target age-range of the programme, 
40%  was screened according to the guidelines, 35% was irregularly screened, and 25% 
never responded to any invitation of the screening programme. One-third of the 
wom en within the target age-range of the screening programme had one or more 
normal smears within the last five years preceding the diagnosis of cervical cancer. 
Reviewing those slides showed that 39% of the smears was again diagnosed as 
normal, 37% showed a more severe cytological abnormality, and 24% was reviewed as 
unsatisfactory for evaluation. This chapter shows that the target age-range, a high 
non-attendance rate, and the relatively low sensitivity of the screening method are 
important reasons that cervical cancer may occur despite a national screening 
programme.
Chapter 3
The optimal treatment strategy for patients diagnosed with atypical squamous cells 
of undetermined significance (ASC-US) remains controversial. Despite triage strategies, 
like repeat cytology or human papillomavirus (HPV) detection, a group with a low risk
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of developing high grade lesions will remain. This chapter describes a 10-year 
follow-up of aggressive versus less aggressive colposcopic management of wom en 
referred with two consecutive ASC-US smears, in order to determine which strategy is 
preferable. An aggressive management for wom en referred with ASC-US, treating all 
colposcopically detected abnormalities, leads to faster normalization of cytological 
smears than the less aggressive management, treating only colposcopically suspected 
high-grade cervical intraepithelial neoplasia (CIN) lesions. However, during ten years 
of follow-up, both groups showed the same percentages of CIN lesions (8.1% vs 8.4%). 
Consequently, initial fast normalization of follow-up smears with aggressive 
management did not show long-term advantages versus less aggressive management 
with respect to the risk of developing cervical cancer. Less aggressive management 
may be preferred because of the non-invasivity. Excisional procedures used to treat 
cervical intraepithelial neoplasia seem to be associated with adverse obstetric 
morbidity, like preterm delivery, low birth weight, and premature rupture of 
membranes. Though, aggressive treatment with faster normalization may take away 
women's concerns, and therefore, may in some cases be preferred.
Chapter 4
W om en do not anticipate abnormal smear results during cervical cancer screening, 
and are often taken by surprise. High levels of anxiety and negative emotional 
responses are experienced at all stages of cervical screening. Referral for colposcopy 
frequently results in fear of cancer and worries about reproduction. In order to reach 
the greatest benefit from the cervical screening program, it seems to be important to 
decrease fear and anxiety after an abnormal smear result. This chapter describes a 
randomized controlled trial conducted to see whether providing targeted information 
on an individual level reduces anxiety in wom en referred to the colposcopy clinic. 
This chapter showed that individually targeted information about the diagnosis and 
procedure by mail and phone did not significantly decrease anxiety scores on the 
Spielberger State and Trait Anxiety Inventory (STAI) and Hospital Anxiety and 
Depression scale (HADS). However, knowledge about HPV and the colposcopy 
procedure did significantly increase by providing individually targeted information. 
Increasing knowledge about the diagnosis and the procedure might cause higher 
attendance rates.
Chapter 5
Multicentric HPV infections affecting vulva, cervix, vagina and anus simultaneously 
have been described previously. A decreased immune response to hrHPV has been 
suggested to be the cause of these multicentric hrHPV infections, although it is also 
possible that HPV affects cervix and vulva consecutively. Vulvar squamous cell 
carcinoma (SCC) develops following two pathways, related to differentiated (d) vulvar
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intraepithelial neoplasia (VIN) or to HPV related usual (u) VIN. This study showed that 
patients with uVIN related vulvar SCCs more often have abnormal cervical smears 
and/or histologically confirmed cervical (pre)malignancies, compared with wom en 
with dVIN/LS related vulvar SCC. Moreover, the hrHPV types that were found in either 
uVIN related vulvar cancer and cervical (pre)malignancies were similar. Even less 
common types of HPV were detected in both specimens, even after an interval of 
more than ten years, and after treatment of the neoplastic lesion. The data in this 
chapter suggest that the identical longstanding hrHPV infection is causing these 
multicentric (pre)malignancies. These multicentric (pre)malignancies emphasize the 
necessity to examine the entire lower female ano-genital tract once a uVIN related 
lesion is found.
Chapter 6
HPV testing in cervical cancer screening has a beneficial effect in patient management 
and may increase the success rate of population-based screening programmes. 
Regarding HPV testing, cervicovaginal self-samples have been proven to be as reliable 
as physician-obtained samples. The introduction of cervicovaginal self-sampling 
might increase the participation rate and may therefore potentially reduce cancer 
incidence.
This chapter describes HPV detection and genotyping of self-sampled genital smears 
subsequently applied to an FTA cartridge. DNA was obtained from the FTA cartridges 
by simple elution as well as extraction. All samples were analysed by the HPV SPF -Line 
Blot 25. Overall agreem ent between self- and physician-obtained samples was 93.3%, 
in favour of the self-samples. Overall agreem ent between FTA cartridge and 
liquid-based medium for hrHPV presence was 100%. Additionally, overall agreement 
between the DNA elution and extraction method was 100%. In this chapter we 
showed that HPV detection and genotyping in self-obtained cervicovaginal samples 
applied to an FTA cartridge is reliable. An advantage is that DNA-elution does not 
require DNA-extraction procedures and is therefore easy, cheap, and fast. Furthermore, 
the FTA cartridge is a convenient dry medium for collection and safe transport by 
ambient temperature. This method may contribute to a new way of cervical cancer 
screening.
Chapter 7
The previous chapter describes a proof-of-principle study with the SPF -Line Blot 25 
assay, to assess the potential of HPV detection directly on eluted DNA from the FTA 
cartridge. However, the SPF10-Line Blot 25 assay is known to be very sensitive in HPV 
detection, and it is important to know how clinically validated hrHPV assays with a 
lower analytical sensitivity perform on FTA cartridge samples. In this chapter, the 
clinically validated hrHPV Hybrid Capture (HC2) and GP5+/6+-PCR assays were applied
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to cervical samples collected on the FTA cartridge. Herewith, the potential use of the 
FTA cartridge of wom en visiting a gynaecologic outpatient clinic was determined. 
FTA cartridge samples were compared with liquid based samples in terms of hrHPV 
detection, and detection of high-grade CIN lesions. There was a reasonably good 
level of concordance in hrHPV detection between liquid based and FTA cartridge 
systems, when using the GP5+/6+-PCR. This level of concordance was much lower 
using HC2. Based on the results so far, HC2 might not be the preferred method for 
hrHPV detection using FTA cartridges. To obtain sufficient (clinical) sensitivity, 
amplification based methods appear to be more suitable, though these methods 
need further optimalization.
Chapter 8
The last chapter comprises the general discussion of the results. These results are 
placed in the light of the current developments within the Dutch cervical cancer 
screening programme. HPV detection together with HPV vaccination will have a 
considerable impact on future cervical cancer screening. Therefore, screening 
algorithms must regularly be re-evaluated and adjusted to the current situation and 
knowledge.
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Samenvatting
Hoofdstuk 1
Baarmoederhalskanker screening werd in Nederland op een nationaal niveau 
ingevoerd in 1988. Momenteel worden vrouwen tussen de 30 en 60jaar iedere vijfjaar 
uitgenodigd voor een uitstrijkje. Afhankelijk van de uitslag worden vrouwen verwezen 
naar de gynaecoloog voor colposcopie, worden vrouwen uitgenodigd voor een 
herhaal uitstrijk na 6 maanden, of gaan vrouwen terug in het bevolkingsonderzoek 
(BVO) en worden opnieuw uitgenodigd na 5 jaar. De incidentie en mortaliteit van 
baarmoederhalskanker is enorm gedaald na de invoering van het BVO.
Hoofdstuk 1 geeft een overzicht van de geschiedenis van baarmoederhalskanker 
screening in Nederland en beschrijft chronologisch de potentiële gaten en valkuilen 
van baarmoederhalskanker screening. De effectiviteit van kanker screening is 
afhankelijk van het leeftijdscohort dat wordt uitgenodigd, het percentage van 
deelname, de gevoeligheid van de test, de frequentie van screening, het opvolgen 
van controles en de effectiviteit van vroege behandeling.
Hoofdstuk 2
Dit hoofdstuk beschrijft de tekortkomingen van het huidige BVO door retrospectief 
de screeningsvoorgeschiedenis van 401 vrouwen met baarmoederhalskanker te 
bekijken. Tweederde van deze vrouwen werd gediagnosticeerd binnen de doelgroep 
van het BVO (leeftijd 30-60 jaar). Zij ontvingen tenminste één uitnodiging. Eén derde 
van de vrouwen met baarmoederhalskanker werd gediagnosticeerd buiten die 
doelgroep. Van de vrouwen binnen de doelgroep was 40%  gescreend volgens de 
richtlijnen van het BVO, 35% was onregelmatig gescreend en 25% had nooit 
gereageerd op de uitnodigingen van het BVO. Eén derde van de vrouwen binnen de 
doelgroep had één of meer normale uitstrijkjes binnen vijfjaar voor de diagnose 
baarmoederhalskanker. Nadat deze uitstrijkjes opnieuw bekeken werden bleek dat 
39% opnieuw als normaal werd afgegeven, 37% bleek afwijkende cellen te laten zien 
en 24% had als kwalitatief onvoldoende afgegeven moeten worden. Dit hoofdstuk 
laat zien dat de leeftijdsgrenzen van de doelgroep, een hoge non-compliance en een 
relatief lage gevoeligheid van de gebruikte screeningsmethode belangrijke redenen 
zijn dat baarmoederhalskanker zich kan ontwikkelen ondanks een nationaal BVO.
Hoofdstuk 3
De optimale behandelingsmethode voor patiënten met "atypical squamous cel Is of 
undetermined significance (ASC-US) is controversieel. Ondanks triage strategieën 
zoals herhaaluitstrijkjes of humaan papillomavirus (HPV) detectie, blijft dit een groep 
met een laag risico op het ontwikkelen van hooggradige laesies. Dit hoofdstuk 
beschrijft een 10-jaars follow-up van agressief versus minder agressief colposcopisch
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beleid bij vrouwen verwezen met twee achtereenvolgende ASC-US uitstrijkjes, 
teneinde te bepalen welk beleid de voorkeur geniet. Een agressief beleid bij vrouwen 
verwezen met ASC-US, ofwel het behandelen van alle colposcopisch zichtbare 
afwijkingen, leidt tot snellere normalisatie van uitstrijkjes dan het minder agressief 
beleid, ofwel behandelen van enkel colposcopisch suspecte hooggradige cervicale 
intraepitheliale neoplasie (CIN) lesies. Echter, gedurende tien jaar follow-up lieten 
beide groepen dezelfde percentages CIN lesies zien (8.1% vs 8.4%). Derhalve liet 
initiële snelle normalisatie van herhaal uitstrijkjes door middel van agressief beleid 
geen voordelen zien ten aanzien van het ontwikkelen van baarmoederhalskanker op 
de lange termijn ten opzichte van minder agressief beleid. Minder agressief beleid 
kan daarmee de voorkeur hebben in verband met de non-invasiviteit. Invasieve 
procedures gebruikt om CIN laesies te behandelen zijn geassocieerd met obstetrische 
morbiditeit, zoals voortijdig bevallen, laag geboortegew icht en het voortijdig breken 
van de vliezen. Toch kan agressief beleid met snelle normalisatie zorgen wegnem en 
en daarmee in sommige situaties de voorkeur hebben.
Hoofdstuk 4
Vrouwen verwachten vaak geen afwijkende uitslag van een uitstrijkje in het BVO en 
worden daardoor vaak verrast. Hoge angstniveaus en negatieve emotionele reacties 
worden gezien gedurende het hele traject van baarmoederhalskanker screening. Een 
verwijzing voor colposcopie resulteert vaak in angst voor kanker en zorgen om een 
toekomstige kinderwens. Om de grootste winst te halen uit het BVO is het belangrijk 
om angst en bezorgdheid na een afwijkend uitstrijkje te reduceren. Dit hoofdstuk 
beschrijft een gerandomiseerde gecontroleerde studie om te kijken of het geven van 
toegespitste informatie op een individueel niveau angst en bezorgdheid kan 
reduceren bij vrouwen die verwezen zijn voor een colposcopie. Dit hoofdstuk laat 
zien dat individueel toegespitste informatie over de diagnose en de procedure via 
post en telefonisch, geen significant lagere score geeft op de 'Spielberger State and 
Trait Anxiety Inventory' (STAI) en de 'Hospital Anxiety and Depression scale' (HADS). 
Echter, de kennis over HPV en de colposcopische procedure nam significant toe bij 
het geven van individueel toegespitste informatie. Een toename in kennis over de 
diagnose en procedure zou een hogere opkomst kunnen bewerkstelligen.
Hoofdstuk 5
Multicentrische HPV infecties die zowel de vulva, cervix, vagina en anus simultaan 
infecteren zijn eerder beschreven. Een afgenomen immuun respons voor HPV is 
gesuggereerd als oorzaak van deze simultane hrHPV infecties, al is het ook mogelijk 
dat HPV de cervix en vulva achtereenvolgens infecteert. Het plaveiselcelcarcinoom 
(PCC) van de vulva verloopt via twee paden, gerelateerd aan de gedifferentieerde (d) 
vulvaire intraepitheliale neoplasie (VIN) of via het HPV gerelateerde usual (u) VIN. Dit
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hoofdstuk laat zien dat patiënten met een uVIN gerelateerd vulvacarcinoom vaker 
afwijkende uitstrijkjes en/of histologisch bevestigde cervicale (pre)maligniteiten 
hebben, vergeleken met vrouwen met een dVIN/LS gerelateerd vulvacarcinoom. 
Bovendien bleken de hoog risico (hr) HPV types die werden gevonden in zowel uVIN 
gerelateerde vulvacarcinomen en bijbehorende cervicale (pre)maligniteiten identiek. 
Zelfs weinig voorkomende HPV types werden gevonden in beide samples, ook na 
een interval van meer dan tien jaar en na behandeling van de neoplastische laesie. De 
data in dit hoofdstuk suggereren dat een identieke langdurige hrHPV infectie deze 
multicentrische (pre)maligniteiten veroorzaakt. Deze multicentrische (pre) 
maligniteiten benadrukken de noodzaak om het gehele ano-genitale stelsel van de 
vrouw te onderzoeken wanneer er sprake is van een uVIN gerelateerde laesie.
Hoofdstuk 6
HPV bepaling bij baarmoederhalskanker screening heeft een toegevoegde waarde 
en zou het succes percentage van het BVO kunnen verhogen. Ten aanzien van HPV 
bepalingen zijn cervicovaginale zelftesten even betrouwbaar gebleken als samples 
afgenomen door de arts. Het introduceren van cervicovaginale zelftesten zou de 
deelname kunnen verhogen en daarmee de incidentie potentieel kunnen reduceren. 
Dit hoofdstuk beschrijft HPV detectie en genotypering op zelf afgenomen cervicova­
ginale uitstrijkjes uitgestreken op een FTA cartridge. DNA werd verkregen van de FTA 
cartridge door zowel eenvoudige elutie als extractie. Alle samples werden getest met 
de HPV SPF -Line Blot 25. De overeenkomst tussen de zelf afgenomen en door de arts 
afgenomen samples was 93.3%, in het voordeel van de zelf afgenomen samples. De 
overeenkomst tussen de FTA cartridge samples en de vloeistof samples voor de 
aanwezigheid voor hrHPV was 100%. Bovendien was de overeenkomst tussen de DNA 
elutie en extractie m ethode 100%. In dit hoofdstuk laten we zien dat HPV detectie en 
genotypering van zelf afgenomen cervicovaginale samples uitgestreken op een FTA 
cartridge betrouwbaar zijn. Een voordeel is dat DNA elutie geen DNA extractie 
procedures vereist en daarmee makkelijk, goedkoop en snel is. Bovendien is de FTA 
cartridge als droog medium geschikt voor veilig transport bij wisselende om gevings­
temperaturen. Deze methode zou bij kunnen dragen aan een nieuwe manier van 
baarmoederhalskanker screening.
Hoofdstuk 7
Het voorgaande hoofdstuk beschrijft een 'proof-of-principle' studie met de SPF -Line 
Blot 25 assay om de potentie van HPV detectie op direct geëlueerd DNA van de FTA 
cartridge te onderzoeken. Het is echter bekend dat de SPF10-Line Blot 25 assay zeer 
sensitief is wat betreft HPV detective en het is belangrijk te weten hoe klinisch 
gevalideerde hrHPV assays met een lagere analytische sensitiviteit werken op de FTA 
cartridge. In dit hoofdstuk hebben we de klinisch gevalideerde hrHPV Hybrid Capture
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(HC2) en GP5+/6+-PCR assays getest op de cervicale samples uitgestreken op de FTA 
cartridge. Hiermee werd de potentie van het gebruik van de FTA cartridge geëvalueerd 
bij vrouwen die de poli gynaecologie bezoeken. FTA cartridge samples werden 
vergeleken met de vloeistof samples, wat betreft hrHPV detectie en detectie van 
hooggradige CIN laesies. Er was een redelijk goede concordantie in hrHPV detectie 
tussen vloeistof en FTA cartridge samples, gebruik makend van de GP5+/6+-PCR. 
Deze concordantie was aanzienlijk lager wanneer gebruik werd gemaakt van HC2. 
Gebaseerd op de resultaten tot dusver lijkt HC2 niet de geschikte m ethode voor 
hrHPV detectie met de FTA cartridges. Om voldoende (klinische) sensitiviteit te 
verkrijgen lijken op amplificatie gebaseerde m ethoden meer geschikt, maar is het 
nodig deze m ethoden nog verder te optimaliseren.
Hoofdstuk 8
Het laatste hoofdstuk omvat de algem ene discussie van de resultaten. Deze resultaten 
zijn geplaatste in het licht van de huidige ontwikkelingen van het Nederlandse BVO 
baarmoederhalskanker. HPV detectie samen met HPV vaccinatie zullen een grote 
impact hebben op de toekomstige baarmoederhalskanker screening. Zodoende 
moeten screening algoritmes regelmatig opnieuw geëvalueerd en aangepast worden 
aan de huidige situatie en kennis.
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